European Neuropsychopharmacology (v.23, #S2)
P.3.c.003 Pharmacological modulation of Kv3 potassium channels regulates the firing of parvalbumin-positive fast-spiking interneurons by C.H. Large; M. Rosato-Siri; C. Virginio; E. Zambello; C. Mutinelli; G.S. Alvaro (S454-S455).
P.3.c.002 Disruption of low frequency oscillations by phencyclidine: mechanisms involved in antipsychotic reversal by L. Lladó-Pelfort; E. Troyano-Rodríguez; N. Jurado; F. Artigas; P. Celada (S454).
P.3.c.004 A mechanism of antipsychotic treatment failure and its reversal by D. Amato; F. Canneva; S. Maschauer; L. Chiofalo; S. Huber; A. Rümler; J. Kornhuber; S. Von Hörsten; O. Prante; C. Müller (S455).
P.3.c.006 Inhibitors of SNARE assembly as potential drugs for schizophrenia treatment: a screening study by A. Ramos-Miguel; A.M. Barr; A.J. Dwork; G.B. Rosoklija; J.J. Mann; N. Honson; T.A. Pfeifer; W.G. Honer (S456).
P.3.c.008 Concentration-dependent contribution of human cytochrome P450 isoenzymes to the metabolism of levomepromazine by J. Wójcikowski; A. Basinska; W.A. Daniel (S457).
P.3.c.007 Increased oxidative stress in schizophrenic patients treated simultaneously with haloperidol and the second generation antipsychotics by V. Djordjevic; D. Lazarevic; L.J. Trajanovic; O. Zikic; V. Cosic; P. Vlahovic; B.V. Djordjevic (S456-S457).
P.3.c.001 Pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579 by F. Noël; T.E.T. Pompeu; F.R.S. Alves; C.D.M. Figueiredo; C.B. Antonio; V. Herzfeldt; S.M.K. Rates; E.J. Barreiro; C.A.M. Fraga (S453).
P.3.b.039 Relationship of stress, cannabis use and first psychotic episode by M. Selakovic; D. Dikeos (S452-S453).
P.3.b.035 Temperament, character and neurological soft signs in patients with schizophrenia and unaffected siblings by F. Pastoriza; L. Galindo; D. Bergé; A. Mané; M. Picado; A. Bulbena; O. Vilarroya; C.R. Cloninger (S450).
P.3.b.034 Insight, treatment outcomes and recovery in first-episode schizophrenia by O. Agid; C.O. Siu; P.D. Harvey; R.B. Zipursky; G. Remington (S449).
P.3.b.036 Medication adherence in schizophrenia: relationship with clinical variables and insight by J. Chang; C.H. Kim; D. Roh (S450-S451).
P.3.b.037 Neuroinflammation in schizophrenia: a PET study with [18F]-FEPPA by M. Kenk; T. Selvanathan; N. Rao; I. Suridjan; P.M. Rusjan; A.A. Wilson; S. Houle; R. Mizrahi (S451).
P.3.b.038 Effect of current antipsychotic medication on adaptive salience processing in first-episode of psychosis individuals by R. Smieskova; J. Roiser; C.H. Chaddock; A. Schmidt; S. Borgwardt (S452).
P.3.d.001 The effects of adjuvant treatment with L-triiodothyronine (T3) on acute schizophrenia treatment with risperidone by V. Steibliene; R. Bunevicius; N. Mickuviene; A. Savickas (S457-S458).
P.3.d.002 Clinical predictors of therapeutic response to clozapine in a sample of 42 patients with treatment-resistant schizophrenia by J. Nakhli; L. Ltaief; L. Ben amor; S. Bouhlel; S. Ben Nasr; B. Ben Hadj Ali (S458-S459).
P.3.d.011 Reasons for aripiprazole discontinuation – a retrospective review by A. Millier; B. Briquet; N. Cadi-Soussi; V. Murthy; M. Toumi (S464).
P.3.d.010 The need for educating schizophrenic patients on the side effects of medications by Y. Hashimoto; S. Terawaki; T. Tanimizu; M. Hashimoto; M. Tensho (S463-S464).
P.3.d.012 Direct and indirect meta-analyses comparing metabolic side effects of lurasidone with other second generation antipsychotics by N.V. Murthy; A. Agyemang; A. Inamdar; M. Fallon; H. Andersson (S464-S465).
P.3.d.013 Effect of risperidone or blonanserin on cognitive function and psychotic symptoms in patients with acute phase schizophrenia by H. Hori; K. Yamada; D. Kamada; Y. Shibata; A. Katsuki; R. Yoshimura; J. Nakamura (S465).
P.3.d.014 Efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia: a 13-week double-blind study by A. Wakamatsu; N. Takahashi; M. Takahashi; T. Saito; M. Iizumi; Y. Saito; H. Shimizu; T. Matsumura (S466).
P.3.d.009 Olanzapine versus risperidone: weight gain and BMI of schizophrenic patients in a 24-week trial by D. Siladji-Mladenovic; V. Knezevic; A. Ivezic; S. Drezgic-Vukic (S463).
P.3.d.008 Reproductive side effects of antipsychotic-induced hyperprolactinemia; a cross-sectional study – preliminary results by E. Rubio-Abadal; G. Saenz Navarrete; B. Arranz; N. Del Cacho; R. Cambra; R. Iniesta; M. Roca; V. Barneda; J. Usall (S462).
P.3.d.004 A 57-week, open-label evaluation of paliperidone palmitate flexible-doses in Japanese patients with schizophrenia by A. Wakamatsu; N. Takahashi; M. Takahashi; T. Saito; M. Iizumi; Y. Imai; Y. Saito; T. Matsumura (S459-S460).
P.3.d.003 Managing the introduction of new antipsychotics to a health economy by R. Hodgson; P. Rajkumar; R. Atikum (S459).
P.3.d.005 Paliperidone palmitate versus conventional depots in patients with schizophrenia: a 12 months study by S.L. Romero Guillena; B.O. Plasencia Garcia de Diego; A. Fernandez Galvez (S460).
P.3.d.006 A randomized clinical trial of histamine 2 receptor antagonism in treatment resistant schizophrenia by K. Meskanen; H. Ekelund; J. Laitinen; P.J. Neuvonen; J. Haukka; P. Panula; J. Ekelund (S461).
P.3.d.007 Efficacy of cariprazine on PANSS items and Marder factors: post hoc analysis of a double-blind, placebo-controlled trial in schizophrenia by J. Kane; L. Citrome; R. Litman; S. Zukin; K. Lu; A. Ruth; K. Nagy; I. Laszlovszky; S. Durgam (S461-S462).
P.3.b.033 Drug and alcohol abuse or dependence in psychiatric inpatients by M.C. Garcia Mahia; E. Roman Fernandez; M. Vidal Millares (S448-S449).
P.3.b.032 Hippocampal myo-inositol and glutamate concentrations are predictive of positive symptom severity in ultra-high risk for psychosis by I.M. Bakker; O.J.N. Bloemen; M. De Koning; T.A.M.J. Van Amelsvoort (S448).
P.3.b.013 Risperidone in long-acting injectable form and treatment-resistant schizophrenia with dopamine supersensitivity psychosis by H. Kimura; N. Kanahara; N. Komatsu; K. Muneoka; H. Yamanaka; T. Suzuki; H. Komatsu; Y. Sekine; H. Watanabe; M. Iyo (S436-S437).
P.3.b.012 An association between polymorphisms of the interleukin 1 genes complex and schizophrenia by P. Kapelski; M. Skibinska; J. Hauser (S436).
P.3.b.014 Premorbid adjustment is different in bipolar disorder with psychotic symptoms and schizophrenia by P. Landi; G. Rutigliano; G. Papi; A. Callari; L. Dell'Osso; D. Marazziti (S437).
P.3.b.015 Validation of a technique for the determination of plasma cotinine levels in patients with first episode psychosis by M. Bustillo; A. Zabala; R. Segarra; J. García; J. Cartón; M. Alonso; B. Santos; A. Ugarte; A. Gonzalez-Pinto; M. Gutiérrez (S438).
P.3.b.016 Low low-density lipoprotein (LDL) as a predicting factor for early onset schizophrenia by V. Slavkovic; P.J. Nikolic; S. Manojlovic; D. Gugleta; V. Sibinovic (S438-S439).
P.3.b.011 Association study of transforming growth factor-beta gene polymorphisms in schizophrenia by P. Kapelski; M. Skibinska; J. Hauser (S435-S436).
P.3.b.010 Predictors of acute response to treatment in first episode of psychosis by A. Mane Santacana; D. Berge Baquero; P.C. Garnier Lacueva; P. Salgado Serrano; R. Cortizo Vidal; A. Bulbena Vilarrassa (S435).
P.3.b.006 NGF and BDNF as markers of long-term functionality in first-episode psychosis patients with/without cannabis consumption by M. Martinez-Cengotitabengoa; M. Saenz; M. Fernández; S. Ruiz de Azua; A. Ugarte; P. Vega; C. Bermúdez; A. García-Alocén; A. Gonzalez-Pinto (S432-S433).
P.3.b.005 Oxidative stress at the first psychotic episode: long-term implications by M. Martinez-Cengotitabengoa; S. Alberich; S. Barbeito; J.A. Micó; C. Arango; D. Fraguas; I. Gonzáxlez-Ortega; A. González-Pinto (S431-S432).
P.3.b.007 Duration of untreated psychosis and sexual dysfunction among male patients by V. Sibinovic; S. Tosic-Golubovic; V. Slavkovic; G. Selimovic; T. Mladenovic (S433).
P.3.b.008 NMDA receptor antagonists interventions in schizophrenia: meta-analysis of randomised, placebo-controlled trials by T. Kishi; N. Iwata (S433-S434).
P.3.b.009 Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia by T. Kishi; N. Iwata (S434).
P.3.b.017 Sex-differences in the relationship between cortisol awakening response and working memory in subjects with early psychosis by I. Montalvo; M. Creus; M. Solé; T. Feliu; J. Franch; E. Vilella; A. Gutiérrez-Zotes; J. Labad (S439-S440).
P.3.b.019 Insight mediates link between stigma and depression in schizophrenia by D. Krupchanka; M. Katliar (S440).
P.3.b.028 Transcultural study of clinical and psychosocial aspects of schizophrenia: comparison of patients in Armenia and Belarus by K. Mironava; A. Melik-Pashayan; E. Tarasevich (S445-S446).
P.3.b.027 Antipsychotic treatment and psychosocial functioning in schizophrenia – results from the Romanian cohort of the EUFEST study by V. Matei; A.I. Mihailescu (S445).
P.3.b.029 Antipsychotics, metabolic syndrome and schizophrenia: investigating the role of SREBF polymorphisms by M. Spangaro; R. Cavallaro; C. Guglielmino; F. Cocchi; C. Lorenzi; A. Pirovano; E. Smeraldi; M. Bosia (S446).
P.3.b.030 Change in the pharmacotherapy of schizophrenia patients over a period of 10 years by D. Ceylan; A. Aktener; B. Akdede; K. Alptekin (S446-S447).
P.3.b.031 Neuropsychological profile in psychosis risk syndrome in a child and adolescent sample by J. Tor; A. Sintes; O. Puig; C. Espelt; D. Muñoz; M. Rodríguez; E. De la Serna; B. Sánchez; M. Dolz; I. Baeza (S447-S448).
P.3.b.026 Awareness of illness in first-episode schizophrenia – the relationship with psychopathology by C. Crisan; I. Miclutia; R. Macrea; S. Pintea (S444-S445).
P.3.b.025 Relation between antipsychotic polypharmacy, symptom domains and the quality of life in schizophrenia and schizoaffective disorder by D. Ceylan; S. Yesilyurt; B. Akdede; A. Topuzoglu; Z. Sayin; M. Diriöz; K. Alptekin (S443-S444).
P.3.b.021 “Doctor, I have bugs that caused me cancer!” – clinical case of delusional infestation by T. Reis; S. Marques; D. Barrocas; J. Góis (S441).
P.3.b.020 Description of clinical characteristics and treatment of a sample of adolescents with psychosis risk syndrome by I. Baeza Pertegaz; E. De la Serna; G. Sugranyes; O. Puig; V. Sánchez-Gistau; D. Ilzarbe; J. Tor; M. Espadas; M. Carulla; M. Dolz (S440-S441).
P.3.b.022 Structural differences between patients with persistent auditory verbal hallucinations and stable schizophrenic patients by A. Keymer; M. Serra; F. Nuñez; E.M. Grasa; A. Roldán; S. Vieira; E. Aguilar; G. García; B. Gómez; I. Corripio (S442).
P.3.b.023 Structural analysis of nucleus accumbens in antipsychotic-naive first episode psychosis and clinical correlations by F. Sem; D. Bergé; L. Igual; C. Canals; A. Mané; D. Guinart; O. Vilarroya; M. Forns (S442-S443).
P.3.b.024 Short term benefits of cognitive remediation therapy in schizophrenia by I. Miclutia; N. Ghirasim (S443).
P.3.d.015 Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review by T. Mukai; T. Kishi; Y. Matsuda; N. Iwata (S466-S467).
P.3.d.016 Clozapine-induced elevated C-reactive protein and fever mimicking infection by M.S. Matej Stuhec (S467).
P.3.d.053 Olanzapine concentrations collected postmortem in patients treated with olanzapine long-acting injection by D.P. McDonnell; H.C. Detke; D.M. Falk; C.C. Shatapathy (S489-S490).
P.3.d.052 Prolonged delirious state after olanzapine pamoate injection as a consequence of pro-inflammatory cytokine secretion? A case report by T. Sobanski; B. Wenda; I. Dafov; G. Wagner (S489).
P.3.e.001 A novel Kv3 ion channel modulator restores cognitive function in an animal model of cognitive impairment in schizophrenia by J. Neill; B. Grayson; S. Marsh; M.K. Harte; C. Large (S490).
P.3.e.002 The psychosocial rehabilitation of people with severe mental illness: a study of the impact of an assertive community treatment program by R. Marginean; O. Marginean (S491).
P.3.f.001 Catechol-O-methyltransferase [rs4680] and methylenetetrahydrofolate reductase [rs1801133] polymorphisms interact on elevated plasma homocysteine in schizophrenia by D. Kontis; E. Theochari; S. Kleisas; E. Fryssira; C. Sofocleous; A. Gazi; D. Kypraios; L. Boniatsi; A. Chaidemenos (S492).
P.3.e.003 The cost and effects of atypical antipsychotic agents in patients with schizophrenia in Slovenia: a cost effectiveness study by M. Stuhec; D. Petrica; J. Toni (S491-S492).
P.3.d.051 Lurasidone in the treatment of early-stage schizophrenia: a post-hoc analysis of three pooled acute treatment studies by J. Lieberman; A. Pikalov; J. Hsu; J. Cucchiaro; P. Werner; F. Grossman; A. Loebel (S488-S489).
P.3.d.050 Amisulpride augmentation of clozapine in violent schizophrenia patients: a case-series from the United Kingdom by R. Brooman-White; P. Simpson; J. Hotham; M. Das (S487-S488).
P.3.d.046 Lurasidone for the treatment of schizophrenia: pooled analysis of short-term, placebo-controlled trials by V. Murthy; J. Cucchiaro; A. Pikalov; J. Xu; A. Loebel (S485-S486).
P.3.d.045 Early improvement predicts endpoint response to lurasidone in schizophrenia: pooled analysis of five double-blind trials by C. Correll; P. Werner; A. Pikalov; J. Hsu; J. Cucchiaro; A. Loebel (S485).
P.3.d.047 Switching to lurasidone in patients with schizophrenia: tolerability and effectiveness at 6 weeks and 6 months by J.P. McEvoy; L. Citrome; D. Hernandez; J. Hsu; P. Werner; A. Pikalov; J. Cucchiaro; C.U. Correll; A. Loebel (S486).
P.3.d.048 Expected and effective plasma concentrations of antipsychotics and changes in psychopathology by A. Kaufmann; M.A. Rettenbacher; N. Yalcin; F. Biedermann; M. Edlinger; G. Kemmler; C.G. Widschwendter; S.W. Toennes; W.W. Fleischhacker; A. Hofer (S486-S487).
P.3.d.049 Expected and effective plasma concentrations of antipsychotic drugs and attitude toward treatment by N. Yalcin-Siedentopf; M.A. Rettenbacher; A. Kaufmann; F. Biedermann; M. Edlinger; G. Kemmler; F. Wartelsteiner; C.G. Widschwendter; W.W. Fleischhacker; A. Hofer (S487).
P.3.f.003 Comparison of attitudes toward long-acting injectable antipsychotics among psychiatrists and patients by J.Y. Lee; S.W. Kim; J.M. Kim; J.S. Yoon; Y.H. Lee (S492-S493).
P.3.f.004 Three years follow-up in schizophrenic patients: predictors of recovery by D. Cannavò; C. Concerto; O. Bianchini; E. Aguglia (S493-S494).
P.3.f.013 Burden of diabetes and cardiovascular diseases in schizophrenia and bipolar patients: analysis of health registers in Sweden by N. Bent-Ennakhil; M.C. Périer; P. Sobocki; G. Johansson; D. Milea; J.P. Empana (S498-S499).
P.3.f.012 Association between bilirubin and schizophrenia: a longitudinal study by A. Hofer; C.G. Widschwendter; M.A. Rettenbacher; M. Edlinger; G. Kemmler; W.W. Fleischhacker (S498).
P.3.f.014 Twenty-five years of the Positive and Negative Syndrome Scale: an overview of its use in randomised clinical trials by S. Piras; G. Casu; E. Nicotra; G. Marchese (S499-S500).
P.3.f.015 Abnormal functioning of the default mode network in schizophrenia and unaffected relatives: a study of functional magnetic resonance by L. Galindo; N. Roe; F. Pastoriza; D. Berge; M. Picado; A. Mane; A. Bulbena; O. Vilarroya (S500-S501).
P.3.f.016 AKT1 gene polymorphism and metabolic syndrome in patients with schizophrenia and bipolar disorder by T. Youn; N.Y. Lee; I.W. Chung; Y.S. Kim; S.H. Kim; Y.M. Ahn; H.S. Jun; E.K. Ji (S501).
P.3.f.011 Social anxiety disorder in first episode psychosis: prevalence, relationship with paranoia and perceived shame from psychosis by W.S.D. Chung; S.C. Chan; Y.C. Wong; H.M. Wong (S497-S498).
P.3.f.010 Outcomes of a diet and fitness program for patients with schizophrenia by R. Amiaz; Y. Karni; M. Weiser (S497).
P.3.f.006 Outpatient treatment of psychotic disorders – biological and general health data on antipsychotic treatment by A. Falces; R. Borrego; T. Sarmiento; M.J. Reyes; C. Conesa; T. Bel; T. Corominas (S494-S495).
P.3.f.005 Risperidone and haloperidol extrapyramidal side effects: clinical study by D. Marinkovic; S. Totic; M. Marjanovic (S494).
P.3.f.007 Association between metabolic disease and cardiovascular risk in patients with schizophrenia treated with antipsychotics by A. Vataire; S. Ferchichi; K. Desroziers; N. Cadi-Soussi; V. Murthy; M. Toumi (S495).
P.3.f.008 Clinical and therapeutic outcomes of 61 patients hospitalised for first-episode psychosis by A. Mhalla; M. Abbes; A. Mechri; L. Gaha (S495-S496).
P.3.f.009 Charles Bonnet syndrome: successful treatment of visual hallucinations due to vision loss with escitalopram in three cases by H.C. Hsu; Y. Huang; W. Fan; T. Chen (S496-S497).
P.3.d.044 A randomised, double-blind, placebo controlled, cross-over trial of adjunctive L-arginine in schizophrenia by Y. Kocyigit; Y. Ayhan; G. Yoca; S. Karahan; M.K. Yazici (S484).
P.3.d.043 Metabolic changes in patients with schizophrenia 24 weeks after switching to paliperidone extended release by H.J. Lee; E.Y. Kim; D.C. Jung; Y.M. Ahn (S483-S484).
P.3.d.025 Polypharmacotherapy in hospital treatment of schizophrenia by D.J. Siladji-Mladenovic; V. Knezevic; S. Drezgic-Vukic; A. Ivezic (S472-S473).
P.3.d.024 Relationship between changes in metabolic parameters and changes in symptoms after switching to paliperidone extended-release by N.Y. Woo; Y.M. Ahn; E.Y. Kim; D.C. Jung; Y.C. Hwang; T. Youn (S472).
P.3.d.026 Comparative effectiveness of long-term treatment with atypical antipsychotics in patients with schizophrenia by A. Pikalov; L. Citrome; J. Hsu; P. Werner; J. Cucchiaro; A. Loebel (S473).
P.3.d.027 Aripiprazole once-monthly for schizophrenia: a double-blind, randomised, non-inferiority study versus oral aripiprazole by T. Peters-Strickland; W.W. Fleischhacker; R. Sanchez; N. Jin; R.A. Baker; B. Johnson; J.Y. Loze; R.D. McQuade; W.H. Carson; J.M. Kane (S473-S474).
P.3.d.028 Personal and social performance in schizophrenia: double-blind, non-inferiority study of once-monthly vs oral aripiprazole by W.W. Fleischhacker; R. Sanchez; N. Jin; T. Peters-Strickland; B.R. Johnson; A. Eramo; J.Y. Loze; R.D. McQuade; W.H. Carson; J. Kane (S474-S475).
P.3.d.023 Paliperidone extended release-induced transient leucopenia: a case report by P. Jelenko Roth; M.Z. Dernovsek (S471-S472).
P.3.d.022 Pharmacological treatment of acute agitation in schizophrenia by O. Bianchini; S. Porcelli; E. Aguglia; D. De Ronchi; A. Serretti (S470-S471).
P.3.d.018 Effect of the DRD2 polymorphisms on perospirone and aripiprazole efficacy for Japanese schizophrenia patients – Results of an RCT by Y. Takekita; M. Kato; S. Nonen; M. Wakeno; S. Sakai; G. Okugawa; J. Azuma; T. Kinoshita (S468).
P.3.d.017 Screening for metabolic risk factors in women treated for schizophrenia by B. Batinic; M. Djeric-Jeremic; D. Duisin; G. Opacic (S467-S468).
P.3.d.019 Reboxetine add-on to clozapine in treatment of negative symptoms of schizophrenia: a preliminary open-label study by D. Quattrone; A. Bruno; U. Micò; G. Pandolfo; G. Scimeca; M.R. Muscatello; R. Zoccali (S469).
P.3.d.020 Safety of blonanserin (BNS) and paliperidone extended-release (PAL-ER) in patients with acute schizophrenia by K. Sanada; A. Iwanami; K. Saito; T. Morita; K. Azuma; T. Yoshizawa; T. Tamura; A. Tsukurimichi; Y. Kawamura; E. Uchida (S469-S470).
P.3.d.021 Early improvement as a predictor of treatment response and remission in patients with acute schizophrenia: effects of asenapine by S. Leucht; J. Zhao (S470).
P.3.d.029 Potential treatment with extended-release D2/D3 receptor agonist for tardive dystonia by A. Okato; H. Kimura; M. Takase; N. Kanahara; H. Watanabe; M. Iyo (S475).
P.3.d.030 Efficacy and safety of yokukansan (TJ-54) for treatment-resistant schizophrenia: a randomised placebo-controlled trial by T. Miyaoka; M. Furuya; J. Horiguchi; R. Wake; S. Hashioka; M. Toyama; T. Daimon; N. Mori; Y. Minabe; M. Iyo (S476).
P.3.d.039 Effects of antipsychotic medications on sexual functioning in schizophrenia patients by N. Keskin; S. Cakmak; L. Tamam; Y.E. Evlice (S481).
P.3.d.038 Bilateral repetitive transcranial magnetic stimulation for auditory hallucinations: a randomised controlled, cross-over study by Y.C. Chung; E.J. Kim; S.U. Yeo (S480-S481).
P.3.d.040 Quality of Life (QoL) of schizophrenic outpatients treated with risperidone or haloperidol by D. Vukic; N. Djokic (S482).
P.3.d.041 Paliperidone combination treatment in clozapine-resistant schizophrenia by D. Karaiskos; E. Tzavellas; A. Liappas; I. Liappas; T. Paparrigopoulos (S482-S483).
P.3.d.042 Low doses of rotigotine in patients with antipsychotic-induced parkinsonism by C. Fini; S. Pallottino; C.L. Telesforo; F. Pompei; F. Pierelli; R. Di Fabio; S. De Filippis (S483).
P.3.d.037 Hospitalization rates in patients switched from oral antipsychotics to aripiprazole once-monthly for schizophrenia by J. Kane; J. Zhao; R.A. Baker; A. Eramo; R.D. McQuade; R. Sanchez; T. Peters-Strickland (S480).
P.3.d.036 Clozapine utilisation in routine clinical practice: golden opportunity or neglected orphan? Real-world outcomes by V. Fricchione Parise; G. Balletta; G. Manna (S479-S480).
P.3.d.032 Discharge rates for patients initiated on long-acting injectable antipsychotics by M. Singh (S477).
P.3.d.031 Ten-year antipsychotic treatment – longitudinal study on metabolic parameters by F. Franza; N. Fiorentino; A. Soddu; V. Fasano; L. Calabrese; M. Iandoli; A. Battista; G. Del Buono (S476-S477).
P.3.d.033 Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, randomised, double-blind, placebo- and active-controlled trial by J.A. Lieberman; A.J. Cutler; S. Wan; R. Migliore; A. Ruth; I. Laszlovszky; G. Nemeth; S. Durgam (S477-S478).
P.3.d.034 How do we treat involuntarily admitted patients with schizophrenia? by B. Frajo-Apor; N. Schabetsberger; G. Kemmler; W. Fleischhacker (S478).
P.3.d.035 Satisfaction with medication by switching of antipsychotics: broad effectiveness trial with aripiprazole in Japan (J-BETA) by M. Moriwaki; N. Iwata (S479).
P.3.b.004 Tractography reveals loss of interhemispheric connectivity associated with glutamatergic dysfunction in schizophrenia by D. Almeida Prado; J. Machado-de-Souza; J.E.C. Hallak (S431).
P.3.b.003 Therapeutic tactics in schizophrenia treatment in 1968–70 and 2010–12 by A. Savelyev; A. Lobko; V. Pashkovskiy; A. Sofronov (S430-S431).
P.2.d.035 Influences of medical comorbidities on the course of bipolar disorder: a two-year prospective follow-up study by B. Cha; J.W. Choi; I.Y. Ahn; T.H. Ha; J.S. Chang; K. Ha (S384).
P.2.d.034 Clock genes polymorphisms associations with suicide attempts in bipolar patients by M. Maciukiewicz; J. Pawlak; M. Dmitrzak-Weglarz; M. Wilkosc; A. Leszczynska-Rodziewicz; D. Zaremba; J. Hauser (S383-S384).
P.2.d.036 Cognitive impairment in patients with depressive and euthymic episodes of bipolar disorder by R. Paunescu; I. Miclutia (S384-S385).
P.2.d.037 Rates and predictors of rehospitalisation in bipolar I patients three years after first admission by E. Nieto; M. Rius; J. Carreras; P. Bonet (S385).
P.2.d.039 Serum thioredoxin levels in manic patients with psychotic symptoms by A. Genc; T. Kalelioglu; A. Tasdemir; N. Karamustafalioglu; F.C. Gungor; E.S. Genc; S. Incir; M. Emul; M.C. Ilnem (S386).
P.2.d.038 Cerebrospinal fluid cytokine concentrations in bipolar disorder patients and healthy controls by A. Isgren; J. Jakobsson; E. Pålsson; C.J. Ekman; A. Johansson; C. Sellgren; K. Blennow; H. Zetterberg; M. Landén (S385-S386).
P.2.d.033 Erythropoetin as a new treatment for cogntive dysfunction in bipolar disorder? by K. Miskowiak; M. Vinberg; L.V. Kessing (S383).
P.2.d.032 Management of postpartum manic episode without cessation of breastfeeding: a longitudinal follow up of drug excretion into breast milk by L. Var; I. Ince; A. Topuzoglu; A. Yildiz (S382).
P.2.d.028 Relating mood to plasma glutathione and BDNF levels in patients with bipolar disorder by N. Singh; A.R. Rosa; W. Whitaker; M. De Brito; A. Lewis; E. Vieta; G.C. Churchull; J.R. Geddes; G.M. Goodwin (S380).
P.2.d.027 Serum glycine and serine levels in patients with bipolar disorder by E. Pålsson; K. Södersten; H. Agren; K. Hashimoto; M. Landén (S379).
P.2.d.029 Serum matrix metalloproteinase-9 (MMP-9) and interferon gamma (IFN-γ) in bipolar mood disorder by A. Remlinger-Molenda; A. Czech-Kucharska; M. Wojcicka; M. Michalak; J. Losy; J.K. Rybakowski (S380-S381).
P.2.d.030 Treatment of bipolar mixed states: review of literature evidence and current guidelines by H. Grunze; J.M. Azorin (S381).
P.2.d.031 Quetiapine's effects on emotional processing and sleep oppose abnormalities seen in bipolar phenotype by P.L. Rock; C.J. Harmer; R.G. Foster; K. Wulff; G.M. Goodwin (S381-S382).
P.2.d.040 Psychiatric patients carrying the CYP2C9*2 allele require lower doses of valproic acid to achieve target plasma levels by G. Rutigliano; M. Del Re; P. Landi; M. Mauri; R. Danesi; L. Dell'Osso (S387).
P.2.d.041 The benefit of physical activity as a treatment of bipolar disorder by E. Oberreither; S. Bengesser; N. Lackner; F. Fellendorf; A. Mitteregger; F. Kattnig; B. Reininghaus; H. Kapfhammer; S. Liebmann-Wallner; E. Reininghaus (S387-S388).
P.2.e.003 Role of 5-HT3 receptors in the mechanism of action of the investigational antidepressant vortioxetine by M.S. Riga; P. Celada; C. Sanchez; F. Artigas (S393-S394).
P.2.e.002 Vortioxetine (Lu AA21004), a multimodal antidepressant: differentiation from current antidepressants in animal models of depression by A. Mørk; A.L. Pehrson; C. Betry; D. David; Y. Li; M. Gulinello; S.C. Leiser; N. Haddjeri; C. Sánchez (S392-S393).
P.2.e.004 Vortioxetine (Lu AA21004) disinhibits pyramidal cell output and enhances theta rhythms and long-term plasticity in the hippocampus by E. Dale; H. Zhang; S.C. Leiser; Y. Chao; C. Yang; N. Plath; C. Sanchez (S394).
P.2.e.005 Expression profiling of the lateral habenula in the chronic mild stress rat model of depression by O. Wiborg; L. Jensen; T. Christensen (S394-S395).
P.2.e.006 Synaptic and mitochondrial plasticity of the hippocampus in a genetic rat model of depression after repeated electroconvulsive seizures by F. Chen; G. Wegener; T.M. Madsen; J.R. Nyengaard (S395).
P.2.e.001 Single dose vortioxetine or ketamine but not fluoxetine increases expression of neuroplasticity related genes in the rat prefrontal cortex by K.G. Du Jardin; N. Liebenberg; H. Müller; C. Sanchez; G. Wegener; B. Elfving (S392).
P.2.d.047 Efficacy and safety of asenapine for the treatment of bipolar disorder type I and co-morbid substance use disorders by M. Di Nicola; O. De Vita; M. Pettorruso; L. De Risio; M. Marconi; A. Bruschi; F. Ruggeri; G. Martinotti; G. Camardese; L. Janiri (S391-S392).
P.2.d.043 Mood stabilisation and oxidative stress parameters in bipolar disorder by S. Bengesser; N. Lackner; E. Oberreither; A. Birner; S. Liebmann-Wallner; S. Zelzer; H. Mangge; H.P. Kapfhammer; B. Reininghaus; E. Reininghaus (S388-S389).
P.2.d.042 Relationship between cognitive deficits and history of manic episodes, suicide attempts and psychosis in bipolar affective disorder by V. Marinescu; M. Vrabie; A. Talasman; R. Vuta (S388).
P.2.d.044 Effect of adverse childhood experiences on white matter microstructure in bipolar disorder by I. Bollettini; S. Poletti; D. Radaelli; C. Locatelli; C. Colombo; F. Benedetti (S389).
P.2.d.045 Lithium during late pregnancy: pharmacokinetics and neonatal outcomes by A. Gonzalez-Rodriguez; M.L. Imaz; M. Guitart; A. Torres; E. Roda; F. Botet; M. Palacio; D. Soy; M. Torra; L.L. Garcia-Esteve (S390).
P.2.d.046 C-reactive protein is elevated in bipolar disorder by A.A. Dargél; R. Tamouza; C. Henry; F. Kapczinski; J. Oliveira; O. Godin; M. Leboyer (S390-S391).
P.2.d.026 Efficacy and safety of low- and high-dose cariprazine in patients with acute mania associated with bipolar I disorder by J.R. Calabrese; P.E. Keck; A. Starace; K. Lu; A. Ruth; I. Laszlovszky; G. Nemeth; S. Durgam (S378-S379).
P.2.d.025 Allopurinol for mania. A randomized trial of allopurinol versus placebo as add-on treatment in manic bipolar patients by S. Burshtein; M. Weiser; A.A. Gershon; G. Marian; N. Vlad; I.G. Grecu; E. Tocari; A. Tiugan; M. Hotineanu; J.M. Davis (S378).
P.2.d.007 Are comorbid insulin resistance and type II diabetes risk factors for refractory bipolar illness? by C. Calkin; M. Ruzickova; C. Slaney; J. Garnham; T. Ransom; M. Alda (S366-S367).
P.2.d.006 The MANACOR study on treatment effectiveness in mania by N. Cruz Culebra; C. Saez; M. Mur; E. Nieto; E. Vieta (S365-S366).
P.2.d.008 Association study of the glycogen synthase kinase-3β gene polymorphism with kidney function in long-term lithium-treated patients by M. Abramowicz; A. Szczepankiewicz; M. Michalak; J. Hauser; J.K. Rybakowski (S367).
P.2.d.009 The predictive role of Val66Met polymorphism on levels of BDNF along treatment of medication-free patients with bipolar disorder by I. Grande; P. Magalhães; I. Chendo; L. Sterzt; G. Fries; K. Cereser; M. Kunz; B. Frey; E. Vieta; F. Kapczinski (S367-S368).
P.2.d.010 Breaking bad news – a valproate reaudit by H. Atturu; D. Odelola; E. Etuk; S. Harris (S368-S369).
P.2.d.005 Comparison of treatment of bipolar disorder between the Venezuelan cohort and the total population of a large multinational longitudinal study (WAVE-bd) by M. Bifano; T. Baptista; X. Vilema; X. Mazzarella; I. Carreira; C. Montes; S. Beluche; E. Vieta (S365).
P.2.d.004 Increased insulin-like growth factor-1 in manic patients with bipolar I disorder by Y.K. Kim; C. Na; S.W. Han; K.S. Na (S364-S365).
P.2.c.013 Effect of the putative lithium-mimetic ebselen on 5-HT neurochemistry in the mouse brain by I. Antoniadou; T. Fowler; E. Cardici; T. Arsiwala; T. Sharp (S362).
P.2.c.012 Evaluation of peripheral biomarkers in bipolar and unipolar depression by B. Schilling Panizzutti; B. Wollenhaupt-Aguiar; B. Pfaffenseller; L. Spanemberg; M.A. Caldieraro; E.A. Vares; M.P. Fleck; M. Kunz; F. Kapczinski; M. Kauer-Sant'Anna (S361-S362).
P.2.d.001 Neurocognitive impairments in bipolar disorder are restricted to a subgroup of patients by T. Sparding; K. Silander; S. Hansen; M. Landén (S362-S363).
P.2.d.002 Can pediatric bipolar-I disorder be diagnosed in the context of posttraumatic stress disorder? A familial risk analysis by J. Biederman (S363).
P.2.d.003 Fractional anisotropy in patients with first episode mania in late life by J. Ramirez-Bermudez; P. Alvarado; O. Marrufo; C. Berlanga; A. Guadamuz; C. Atriano; R. Carrillo; J. Taboada; R. Perez-Esparza (S363-S364).
P.2.d.011 Asenapine versus olanzapine in patients with acute mania by S.L. Romero Guillena; B.O. Plasencia Garcia de Diego; P. Aguilar Valseca; E. Garcia Henche; P. Vaquero Casado; N. Casas Barquero (S369).
P.2.d.012 Clinical implications of the polarity index of drugs in maintenance treatment of bipolar disorder: a naturalistic study by D. Popovic; C. Torrent; C.M. Bonnin; A.M.A. Nivoli; A. Murru; I. Pacchiarotti; M. Valenti; E. Vieta (S369-S370).
P.2.d.021 Lithium monotherapy versus lithium and valproate in manic and mixed states: correlation between serum lithium levels and treatment response by C. Del Grande; L. Musetti; D. Marazziti; M. Muti; G.U. Corsini; L. Dell'Osso (S375).
P.2.d.020 The effectiveness of asenapine in clinical practice: the EXPASEN study by A. Murru; N. Cruz; A. Gonzalez-Pinto; C. De Dios; J.M. Montes; A. Perez; I. Zorrilla; P. Lopez; E. Vieta (S374-S375).
P.2.d.022 Cariprazine effects on YMRS items: results of a pooled analysis of 3 randomized, double-blind, placebo-controlled trials in bipolar mania by P. Keck; S. Zukin; K. Lu; A. Ruth; I. Laszlovszky; G. Nemeth; S. Durg am (S375-S376).
P.2.d.023 Associations between cerebrospinal fluid markers and on-going medical treatment in patients with bipolar disorder by J. Jakobsson; E. Pålsson; M. Bjerke; B. Olsson; C.J. Ekman; C. Sellgren; A.G.M. Johansson; K. Blennow; H. Zetterberg; M. Landén (S376-S377).
P.2.d.024 Long-term safety and tolerability of open-label cariprazine in patients with bipolar I disorder by T.A. Ketter; G.S. Sachs; K. Lu; A. Ruth; I. Laszlovszky; K. Nagy; A. Starace; S. Durgam (S377).
P.2.d.019 Asenapine in the treatment of bipolar 1 disorder: a 12 months study by A. Fernandez Galvez; S.L. Romero Guillena; M.E. Dominguez Ballesteros (S374).
P.2.d.018 Initial and post-treatment serum levels of total oxidant-antioxidant status and oxidative stress index in patients with manic episode by T. Kalelioglu; A. Genc; A. Tasdemir; N. Karamustafalioglu; F.C. Gungor; A. Cansiz; S. Incir; M. Emul; M.C. Ilnem (S373-S374).
P.2.d.014 Genetic variability at IMPA2 and INPP1 genes is associated to lithium response in bipolar patients by E. Jimenez; B. Arias; M. Mitjans; J.M. Goikolea; P.A. Saiz; M.P. Garcia-Portilla; P. Buron; J. Bobes; E. Vieta; A. Benabarre (S370-S371).
P.2.d.013 Clinical factors associated with rapid cycling bipolar disorder by M. Valentí; I. Pacchiarotti; E. Vieta (S370).
P.2.d.015 Cognitive deficits in obese bipolar patients – the impact of body fat distribution by N. Lackner; S. Bengesser; A. Birner; B. Reininghaus; F. Kattnig; F.T. Fellendorf; A. Mitteregger; E. Oberreither; S.J. Wallner-Liebmann; H.P. Kapfhammer; E.Z. Reininghaus (S371-S372).
P.2.d.016 Efficacy of olanzapine monotherapy in the treatment of bipolar depression with varying degrees of manic symptoms by H. Katagiri; M. Tohen; S. Fujikoshi; H. Xue; S. Kanba (S372).
P.2.d.017 Is hyperthymic temperament an alarming sign? by P. Marinova; L.G. Hranov (S372-S373).
P.2.f.001 The effect of antidepressant treatment on quality of life in patients with depressive disorders by H.C. Kim; S.K. Hwang; M.J. Lee; H.J. Jo; T.H. Jun; M.S. Lee; J.M. Kim; H.W. Yim; J.B. Kim (S396).
P.2.f.002 Effect of brain volume-related single nucleotide polymorphisms (SNPs) of glycogen synthase kinase 3 (GSK3)-beta gene on SSRI/SNRI treatment response in major depressive disorder by M. Kato; S. Nonen; Y. Takekita; J. Azuma; T. Kinoshita (S396-S397).
P.2.h.007 Neutrality of agomelatine on QT/QTc interval in healthy young volunteers: results from a randomised double-blind cross-over phase I study by U. Marx; F. Picarel-Blanchot; E. Mocaer; L. Seguin (S419).
P.2.h.006 Emotional stability and openness are associated with severity of depressive and anxiety symptoms in patients with brain tumors by A. Bunevicius; S. Tamasauskas; A. Tamasauskas; V. Deltuva; R. Bunevicius (S418-S419).
P.2.h.008 Demographic, clinical, metabolic and anthropometric characteristics of depressed women with and without type 2 diabetes mellitus by Z. Stankovic; M. Jasovic-Gasic; M. Zamaklar (S419-S420).
P.2.h.009 Assessing psychopathological onset and delay to treatment through the “Psychopathological Onset Latency and Treatment Questionnaire” by L. Oldani; B. Dell'Osso; G. Spagnolin; G. Camuri; B. Benatti; C. Palazzo; C. Arici; C. Dobrea; N. Suardi; A.C. Altamura (S420-S421).
P.2.h.011 Somatic comorbidity in psychiatric outpatients with affective and anxiety disorders by M.C. Garcia Mahia; E. Roman Fernandez; J. Vicente Alba; M. Vidal Millares (S421).
P.2.h.005 Association between suicide frequency and meteorological parameters by C. Lee; P. Kim (S418).
P.2.h.004 The impact of diabetes and prescription patterns of antidepressants on the serious psychiatric outcomes among depressive patients by G.M. Kim; J.M. Woo; S.Y. Jung; J. Ahn (S417-S418).
P.2.g.002 8-OH-DPAT reverses depression-like behavior in prenatally stressed ovariectomized female offspring by J. Fedotova; S. Pivina; N. Ordyan (S414-S415).
P.2.g.001 HMGB1 and IL-17 are the mediators linking redox signalling and inflammation in depression by J. Rybka (S414).
P.2.h.001 A double-blind, randomized, placebo-controlled study of quetiapine XR for the treatment of major depression and fibromyalgia by A. McIntyre; D. Paisley; E. Kuoassi (S415).
P.2.h.002 Comparison of electrocardiogram parameters between lithium-well bipolar patients and healthy controls by K. Altinbas; S. Guloksuz; I.M. Caglar; F.N. Turhan Caglar; E. Kurt; E.T. Oral (S416).
P.2.h.003 Transcranial magnetic stimulation in major depression and vascular depression by C. Concerto; M.C. Costanzo; D. Cannavò; G. Lanza; M. Pennisi; E. Aguglia (S416-S417).
P.3.a.001 Familial liability to psychosis is associated with attenuated dopamine stress signaling in ventromedial prefrontal cortex by J. Lataster; D. Collip; J. Ceccarini; D. Hernaus; D. Haas; L. Booij; J. Van Os; J. Pruessner; K. Van Laere; I. Myin-Germeys (S421-S422).
P.3.a.002 Antidepressant-like effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline in the rat forced swimming test: comparison with citalopram by A. Wasik; J. Michaluk; E. Mozdzen; I. Romanska; L. Antkiewicz-Michaluk (S422-S423).
P.3.a.011 Molecular biomarkers of schizophrenia: from biological signs to novel treatment targets by R. Zakharyan; S. Atshemyan; A. Boyajyan (S428).
P.3.a.010 Large scale quantitative proteomic analysis in human postmortem dorsolateral prefrontal cortex tissue in schizophrenia by R. Pinacho; N. Villalmanzo; J.J. Meana; M. Romeu; J.M. Haro; J. Villén; B. Ramos (S427-S428).
P.3.a.012 Altered default mode network activity in schizophrenia patients by A. Pankow; L. Deserno; F. Bermpohl; M. Walter; F. Schlagenhauf; A. Heinz (S428-S429).
P.3.b.001 Pharmacological management of alcohol dependence in chronic schizophrenia by D. Vasile; O. Vasiliu; A.G. Mangalagiu; B.M. Petrescu; G.A. Sopterean; R.E. Bratu (S429).
P.3.b.002 Duration of untreated psychosis and other factors that influence prognosis in psychotic disorders by E.D. Stefan; L. Dehelean (S430).
P.3.a.009 SP1 and SP4 transcription factors are increased in the postmortem hippocampus of subjects with chronic schizophrenia by R. Pinacho; V. Villalmanzo; E. Valdizán; E. Castro; A. Berengueras; J.M. Haro; I. Ferrer; B. Ramos (S426-S427).
P.3.a.008 Family-based association study of interleukin 6 (IL6) and its receptor functional polymorphisms in schizophrenia in a Polish population by M. Maciukiewicz; M. Skibinska; P. Kapelski; J. Hauser (S426).
P.3.a.004 Phencyclidine activates thalamocortical networks by inhibiting GABAergic neurons in the reticular nucleus of the thalamus by E. Troyano-Rodríguez; N. Santana; L. Lladó-Pelfort; P. Celada; F. Artigas (S423-S424).
P.3.a.003 Decreased functionality of lymphocyte dopamine transporter (DAT) in psychoses by D. Marazziti; A. Callari; P. Landi; S. Silvestri; M. Picchetti; S. Baroni (S423).
P.3.a.005 A deeper look onto schizophrenia mechanisms. Association with immunological related pathway by M. Calabrò; A. Drago; A. Sidoti; A. Serretti; C. Crisafulli (S424).
P.3.a.006 Risk for suicide in male schizophrenia patients and the moderating effect of IQ by R. Yoffe; O. Kapara; N. Werbeloff; A. Reichenberg; K. Ginat; E. Fruchter; M. Davidson; M. Weiser (S425).
P.3.a.007 GABAergic expression is differentially expressed in subregions of the prefrontal cortex in rats sensitized to methamphetamine by T.A. Wearne; L.M. Parker; J.L. Franklin; A.K. Goodchild; J.L. Cornish (S425-S426).
P.2.f.031 Safety and effectiveness of ketamine infusions in multimodal treatment-resistant depression; naturalistic report of 16 infusions by P. Gosek; M. Chojnacka; L. Swiecicki (S413-S414).
P.2.f.030 Are there differences in treatment of acute manic episodes in bipolar patients with or without comorbid borderline personality disorder? by D. Barral; M. Castrillo; B. González; V. Sánchez; M. Rosique; L. López; N. Cruz (S412-S413).
P.2.f.011 Serum levels of BDNF, BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine (MRT) with major depressive disorder (MDD) by A. Katsuki; R. Yoshimura; H. Hori; W. Umene-Nakano; A. Ikenouchi-Sugita; K. Hayashi; K. Atake; J. Nakamura (S402).
P.2.f.010 Long-term open-label study of adjunctive treatment with edivoxetine for patients with major depressive disorder (MDD) who are partial responders to SSRI treatment by S. Ball; S. Atkinson; J.D. Sparks; M. Bangs; C. Goldberger; S. Dube (S401-S402).
P.2.f.013 Clinical evidence for improvement in cognitive dysfunction in patients with major depressive disorder (MDD) after treatment with vortioxetine by R.S.E. Keefe; A.R. Mahableshwarkar; C.K. Olsen (S402-S403).
P.2.f.014 PPP3CC gene in antidepressant response: results from three independent samples by C. Fabbri; D. Albani; R. Calati; C. Crisafulli; S. Kasper; J. Zohar; D. Souery; S. Montgomery; J. Mendlewicz; A. Serretti (S403).
P.2.f.015 A prospective study of escitalopram in treatment resistant depression not responding to venlafaxine by R. Calati; D. Souery; S. Montgomery; S. Kasper; J. Zohar; J. Mendlewicz; A. Serretti (S403-S404).
P. 2.f.009 Treating pharmacoresistant depression in psychogeriatry – should electroconvulsive therapy or intravenous seropram be used? by J. Luzny (S400-S401).
P.2.f.008 Duloxetine increased plasma levels of 3-methoxy-4-hydroxyphenylglycol in patients with major depressive disorder by K. Atake; R. Yoshimura; H. Hori; A. Katsuki; J. Nakamura (S400).
P.2.f.004 Quantitative EEG cordance, a new predictor of antidepressant response to agomelatine? by C.S. Peretti; F. Levy; S. Mouchabac; S. Iglesias; G. Chouinard (S397-S398).
P.2.f.003 Deep transcranial magnetic stimulation (TMS) for treatment resistant depression: a 22-week maintenance study by L. Rabany; E.V. Harel; Y. Bloch; A. Zangen; Y. Levkovitz (S397).
P.2.f.005 Plasma levels of IL-6, 5-HTT gene polymorphism, and SSRIs responses in patients with major depressive disorder by R. Yoshimura; J. Nakamura (S398).
P.2.f.006 Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of association with valproic acid by P. Bozzatello; S. Bellino; F. Bogetto (S399).
P.2.f.007 Psychopharmacological treatment in pregnancy and in breastfeeding: focus on escitalopram by L. Orsolini; F. Bozzi; C. Bellantuono (S399-S400).
P.2.f.016 A naturalistic investigation of Thai depressed patients with agomelatine-based treatment by A. Jariyavilas (S404-S405).
P.2.f.017 Depression comorbid with generalised anxiety disorder. Baseline characteristics and response to treatment: data from the DIMENSION study by P. Courtet; G. Vaiva; E. Corruble; P.M. Llorca; P. Gorwood; F. Bayle (S405).
P.2.f.026 An open clinical trial of adjunctive therapy with aripiprazole in patients with partial remission of major depressive disorder by H. Kim; K.J. Lee (S410).
P.2.f.025 Specificity profile of venlafaxine and sertraline in major depression: meta-regression of double-blind, randomized clinical trials by A. Marsano; S. Gibiino; A. Serretti (S409-S410).
P.2.f.027 Vitamin D treatment of seasonal affective disorder in healthcare professionals: a double-blind randomised placebo-controlled trial by C. Nielsen; T. Frandsen; J.P. Hansen; M. Pareek (S410-S411).
P.2.f.028 Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site, randomised controlled trial by J.W. Murrough; D.V. Iosifescu; L. Chang; R.K. Al Jurdi; C. Green; A. Perez; S.Z. Iqbal; S. Pillemer; A. Foulkes; S. Mathew (S411-S412).
P.2.f.029 A randomised, double-blind, study of vortioxetine versus agomelatine in adults with major depressive disorder (MDD) with inadequate response to SSRI/SNRI treatment by L. Häggström; R.Z. Nielsen; N. Danchenko; L. Poulsen (S412).
P.2.f.024 The effect of group therapy on the depression, quality of life, immunity and heart rate variability (HRV) in Korean patients with breast cancer by S. Lee; H. Lee; W. Bahk (S409).
P.2.f.023 Immediate cerebral blood flow changes induced by deep brain stimulation of subcallosal cingulate gyrus in treatment-resistant depression by M. Serra-Blasco; D. Puigdemont; J. De Diego; J. Molet; Y. Vives; E. Álvarez; V. Pérez; M.J. Portella (S408-S409).
P.2.f.019 How clinical retardation and cognitive attention processes are being connected in a cohort of depressed patients treated by agomelatine by P. Gorwood; P. Courtet; G. Vaiva; E. Corruble; P.M. Llorca; F. Bayle (S406).
P.2.f.018 Self questionnaires during the first 2 weeks of antidepressant can be predictive of later response and remission to agomelatine by P. Gorwood; P. Courtet; G. Vaiva; E. Corruble; P.M. Llorca; F. Bayle (S405-S406).
P.2.f.020 Antidepressant response in two samples of depressed patients, with and without psychotic comorbidity: data from the DIMENSION study by G. Vaiva; P. Courtet; E. Corruble; P.M. Llorca; F. Bayle; P. Gorwood (S406-S407).
P.2.f.021 6 months remission predictors of major depressive episode: data from the D-EXTENSION study by P. Courtet; I. Jaussent; G. Vaiva; E. Corruble; P.M. Llorca; F. Bayle; P. Gorwood (S407).
P.2.f.022 Efficacy of 3 agomelatine dose regimens versus placebo in major depressive disorder (MDD) patients according to the level of severity at baseline by S.H. Kennedy; A. Avedisova; F. Picarel-Blanchot; C. De Bodinat (S408).
P.3.f.017 A multicentric, retrospective data collection from patients diagnosed with schizophrenia switched to amisulpride – SWITCH study by D. Vasile; R.A. Macovei; O. Vasiliu; D. Ojog (S501-S502).
P.3.f.018 Aminotransferase levels as a predictor for the development of metabolic syndrome in patients with schizophrenia by E.Y. Kim; H.Y. Lee; D.C. Jung; Y.M. Ahn; T. Yun (S502).
P.7.b.014 The association between the NR3C1 gene polymorphism and anorexia nervosa or stressful life events by M. Dmitrzak-Weglarz; A. Slopien; A. Szczepankiewicz; M. Tyszkiewicz-Nwafor; J. Hauser (S594).
P.7.b.013 Glycemic control and behaviour and mood disorders in adolescents with diabetes by D. Dronjak; M. Cvetkovic (S593-S594).
P.7.b.015 Comparison between a familial versus a clinical high risk approach to the study of psychosis risk in adolescence by D. Ilzarbe; G. Sugranyes; I. Baeza; E. De la Serna; S. Romero; V. Sanchez-Gistau; M. Dolz; J. Castro-Fornieles (S594-S595).
P.7.b.016 Connectomic disturbances in ADHD combined versus predominantly inattentive type by S. Hong; A. Zalesky; A. Fornito; S. Park; Y. Yang; M. Park; M. Shin; B. Kim; S. Cho; J. Kim (S595-S596).
P.7.b.018 Relationship between clinical factors and psychological problems in children and adolescents with epilepsy and their families by E. Kim (S596-S597).
P.7.b.017 Association of parental stress and emotional and behavioral problems in children and adolescents with epilepsy by E. Kim (S596).
P.7.b.012 A scale for the assessment of hyperfocusing in attention deficit and hyperactivity disorder by E. Ozel-Kizil; H. Demirbas; G. Bastug; S. Kirici; E. Tathan; N. Kasmer; B. Baskak (S593).
P.7.b.011 First episode psychosis during adolescence: clinical and therapeutic differences from adulthood onset by M. García; D. Ilzarbe; S. Mansilla; A. Pérez; M. Fábrega; E. Parellada; G. Sugranyes; I. Baeza (S592-S593).
P.7.b.007 Stress responses in adults with attention-deficit and hyperactivity disorder (ADHD): gender differences by J.A. Ramos-Quiroga; G. Palomar; M. Corominas; R. Ferrer; R. Catalan; A. Real; M. Nogueira; M. Casas (S589-S590).
P.7.b.006 Connection between genetic variations of homocysteine metabolism and progression of schizophrenia by L. Kevere; S. Purvina; D. Bauze; M. Zeibarts; L. Piekuse; I. Purvins (S589).
P.7.b.008 Reduced serotonin transporter binding in adult ADHD investigated by PET and [11C]DASB by G. Kranz; M. Mitterhauser; A. Kutzelnigg; A. Hahn; D. Haeusler; A. Hoeflich; T. Vanicek; W. Wadsak; S. Kasper; R. Lanzenberger (S590-S591).
P.7.b.009 Distinct resting state functional connectivity correlates for specific dimensions of adolescent psychopathy by L.E. Pape; M.D. Cohn; L. Schmaal; W. Van den Brink; T.A.H. Doreleijers; D.J. Veltman; A. Popma (S591).
P.7.b.010 Ascertainment source and clinical correlates of autism spectrum disorders (ASD): a comparative study of ASD youth attending a specialty and a general psychiatry clinic by G. Joshi; J. Wozniak; C. Petty; R. Fried; M. Galdo; K. McDermott; C. Epstein; R. Walker; L.K. Feinberg; J. Biederman (S591-S592).
P.7.b.019 A new computational approach, mGWAS, identifies a novel drug target for autism by B. Bigio; V. Sonakya; M.K. Tonn; C. Nasca; K.M. Wittkowski (S597).
P.7.c.001 Differential electrophysiological effects of atomoxetine and methylphenidate on prefrontal cortex and midbrain dopamine neurons by B. Gronier; M. Di Miceli (S598).
P.7.d.009 Methylphenidate hydrochloride modified release improved inattention and hyperactivity/impulsivity scores in adult ADHD patients by M. Huss; Y. Ginsberg; T. Tvedten; T. Arngrim; M. Greenbaum; A. Philipsen; K. Carter; C.W. Chen; P. Gandhi; V. Kumar (S604-S605).
P.7.d.008 Efficacy of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with ADHD: head-to-head responder analyses by E. Cardo; D. Coghill; P. Nagy; B. Adeyi; C. Anderson; B. Caballero; N. Higgins; P. Hodgkins; R. Civil; R.W. Dittmann (S603-S604).
P.7.d.010 Growth on stimulant medication: effects in children with ADHD by S. Carucci; T. Usala; F. Granitzio; C. Balia; D. Coghill; A. Zuddas (S605).
P.7.d.011 Tolerability, safety and efficacy of long term (at least 6 months) quetiapine and aripiprazole in children and adolescents by E. Sanna; M.G. Atzeni; G.L. Melis; S. Carucci; A. Zuddas (S605-S606).
P.7.d.012 Paliperidone palmitate long-acting injection in adolescents: report of two cases by M. Fabrega Ribera; S. Garcia Chulbi; G. Sugranyes Ernest; I. Baeza Pertegaz (S606-S607).
P.7.d.007 Differences between responders and not responders treated with fluoxetine in a sample of adolescents by A. Blazquez; M.T. Plana; S. Mas; J.A. Arnaiz; A. Lafuente; L. Lázaro (S603).
P.7.d.006 Differential effects on attention over 24 weeks of an NMDA antagonist versus carbamazepine in paediatric epilepsy patients by K. Wesnes; J. Busner (S602).
P.7.d.002 Impact of previous ADHD medication on the efficacy of lisdexamfetamine dimesylate in the treatment of ADHD: post hoc analyses by D. Coghill; T. Banaschewski; M. Lecendreux; C. Soutullo; A. Zuddas; S. Sorooshian; B. Adeyi; L. Squires; R. Civil (S599-S600).
P.7.d.001 Health-related quality of life outcomes in a long-term study of lisdexamfetamine dimesylate in children and adolescents with ADHD by D. Coghill; T. Banaschewski; A. Zuddas; M. Johnson; P. Hodgkins; B. Adeyi; L. Squires; R. Civil (S598-S599).
P.7.d.003 Assessment of effects of atomoxetine in adult patients with ADHD: consistency among 3 geographic regions in a response maintenance study by Y. Tanaka; H. Upadhyaya (S600).
P.7.d.004 Levetiracetam-induced psychiatric adverse events in children with epilepsy by N. Jovic; M. Belacevic (S601).
P.7.d.005 Methylphenidate hydrochloride modified release led to a beneficial impact on family-, work- and social life in adult ADHD patients by M. Huss; Y. Ginsberg; T. Tvedten; T. Arngrim; M. Greenbaum; A. Philipsen; K. Carter; C.W. Chen; P. Gandhi; V. Kumar (S601-S602).
P.7.b.005 The association between gene polymorphisms and visual-spatial functions and organisation of graphomotor actions in ADHD patients by A. Slopien; A.R. Borkowska; M. Dmitrzak-Weglarz; A. Szczepankiewicz; N. Pytlinska; R. Komorowska-Pietrzykowska; F. Rybakowski; A. Rajewski; T. Wolanczyk; J. Hauser (S588-S589).
P.7.b.004 Influence of duration of untreated psychosis (DUP) on functional outcome in youth with first episode psychosis: a 2-year longitudinal study by A. Del Rey-Mejias; D. Fraguas; J. Castro-Fornieles; S. Otero; A. Gonzalez-Pinto; L. Pina-Camacho; C.M. Diaz-Caneja; C. Arango; I. Baeza; M. Parellada (S587-S588).
P.6.d.006 Aripiprazole plus topiramate in opioid-dependent patients with schizoaffective disorder: evidence from a pilot study by F. Cordova; A. Bruno; V.M. Romeo; G. Pandolfo; G. Scimeca; M.R.A. Muscatello; R.A. Zoccali (S577).
P.6.d.005 Differential effects of short- and long-term cocaine use on cortical volume, thickness and surface area by A.M. Kaag; C.L. Crunelle; W. Van den Brink; J. Homberg; L. Reneman (S576).
P.6.d.007 Fertilizers as a pathoplastic factor of psychosis by S. Marques; T. Reis; D. Barrocas; J. Góis (S577-S578).
P.6.e.001 Decision-making, affective temperament and cognitive function in patients with alcohol or opiate dependence by A. Kalwa (S578).
P.6.e.002 Substance abuse patterns among university students: regional and gender differences by A. Unger; L. Brandt; A. Matznetter; C. Zachbauer; G. Fischer; R. Jagsch (S578-S579).
P.6.d.004 Pharmacogenetics of treatment of opioid dependence with oral naltrexone and long acting sustained release naltrexone implant by E. Krupitsky; E. Zvartau; E. Blokhina; D. Nielsen; T. Kosten; G. Woody (S575-S576).
P.6.d.003 In vivo evidence for long-term CNS toxicity associated with chronic binge use of methamphetamine by W. Hahm; J.H. Kim; W.Y. Won; K.D.J. Kim (S575).
P.6.c.013 The effects of the new synthetic drugs mephedrone, methylone, naphyrone and 5,6-methylenedioxy-2-aminoindane (MDAI) in rats by T. Palenicek; F. Tyls; M. Fujakova; E. Lhotkova; L. Kaderabek; A. Kubesova (S572-S573).
P.6.c.012 Stereological characterisation of c-Fos expression in the nucleus accumbens and orbitofrontal cortex in mice after cocaine treatment by R. Santos; R. Frussa-Filho; A.V. Silva; C.L. Patti; E.A.V. Marinho; A.W. Hollais; T.S. Yokoyama; A.J. Oliveira-Lima; F. Talhati; B.M. Longo (S571-S572).
P.6.c.014 Effects of neuregulin-1 gene functional variant on illicit substance use in a longitudinal population-representative study by M. Vaht; E. Kiive; T. Kurrikoff; J. Parik; T. Veidebaum; J. Harro (S573).
P.6.d.001 Inhibition-specific prefrontal connectivity after an acute dose of heroin by A. Schmidt; S. Borgwardt; O. Schmid; G.A. Wiesbeck; A. Riecher-Rössler; K. Bendfeldt; R. Smieskova; U.E. Lang; K. Rubia; M. Walter (S573-S574).
P.6.d.002 D3 receptor genotype (rs6280) impact on ventral striatal and amygdala volumes in abstinent cocaine dependent individuals by A. Verdejo-Garcia; L. Moreno-Lopez; N. Albein-Urios; B. Gutierrez; C. Soriano-Mas (S574-S575).
P.6.e.003 Modafinil induces the rapid-onset type of behavioral sensitization in mice by R. Wuo-Silva; D.F. Fukushiro; R. Santos; A.W. Hollais; S.B. Grapiglia; E. Mari-Kawamoto; L.B. Lopes-Silva; J.M. Costa; L.R.A. Bittencourt; R. Frussa-Filho (S579).
P.6.e.004 Glutamate and GABA alterations in the dorsal anterior cingulate cortex in nicotine dependence by M.H.J. Ter Mors-Schulte; A.E. Goudriaan; W. Van den Brink; R.W. Wiers; L. Schmaal (S580).
P.7.a.003 Affinity of alpha-MSH-reactive immunoglobulins in eating disorders and their effects on melanocortin 4 receptor signaling by N. Lucas; R. Legrand; K. Akkermann; N. Tennoune; P. Déchelotte; J. Harro; S.O. Fetissov (S585).
P.7.a.002 Perinatal maternal DSM-IV anxiety and depressive disorders and regulatory disorders in the offspring by J. Petzoldt; H.U. Wittchen; J. Wittich; J. Martini (S584-S585).
P.7.b.001 Clinical characteristics of depression among adolescent females: a cross-sectional study by M. Rabie; A.H. Khalil; M.F. Abd-El-Aziz; T.A. Abdou; A.H. El-Rasheed; W.M. Sabry (S585-S586).
P.7.b.002 Can autistic traits be identified in children with ADHD? A controlled study by J. Biederman (S586-S587).
P.7.b.003 Screening for autism in preterm children with birth weights less than 1500 g by I. Dudova; M. Kasparova; D. Markova; J. Lukaskova; S. Beranova; T. Urbanek; M. Hrdlicka (S587).
P.7.a.001 Pharmacological treatment versus neurofeedback in typical symptomatology of attention deficit hyperactivity disorder by E. Cardo; M. Servera; M. Bernad; V. Meisel (S584).
P.6.f.006 Interaction between the stress level and the severity of nicotine dependence and type of smoking behavior among students by I. Ritkis; A. Vasylyeva; S. Tabachnikov; A. Gurkova (S583-S584).
P.6.f.002 Clinical and therapeutic impact of substance abuse on patients with first-episode psychosis by A. Mhalla; I. Ben Mahmoud; L. Gassab; A. Mechri; L. Gaha (S581).
P.6.f.001 The changes of blood glucose control and lipid profiles after short-term smoking cessation in healthy males by I. Paik; W. Hahm; S. Kim; S. Kwak; D. Kim (S580-S581).
P.6.f.003 Management of smoking reduction and cessation in inpatients with schizophrenia: impact of electronic cigarettes by G. Minutolo; P. Caponnetto; R. Auditore; C. Russo; R. Polosa (S581-S582).
P.6.f.004 Association between legal substance use and mental disorders: are there differences between recently deployed and non-deployed soldiers? by S. Trautmann; S. Schönfeld; S. Behrendt; H.U. Wittchen (S582).
P.6.f.005 Explicit claims for tamper resistant and abuse deterrent opiates: FDA draft guidance by E.M. Sellers; M.K. Romach (S583).
P.7.d.013 The effect of treatment duration on methylphenidate discontinuation in adults with ADHD: a meta-analysis by R. Cunill; X. Castells; D. Capellà (S607).
P.7.d.014 Efficacy and safety of rTMS in children and adolescents with medication-resistant Tourette disorder: an open-label, prospective study by W.S. Seo; J.Y. Baek (S607-S608).
C.03.02 From hopelessness to hope: a patient-centred approach by R.H. McAllister-Williams (S632).
C.03.01 How confidently can we predict response in patients with MDD? by P. Gorwood (S631).
C.03.03 New pharmacotherapeutic opportunities for the treatment of depression by B.E. Leonard (S632).
C.04.01 Protecting patients from the long-term consequences of schizophrenia by J.M. Kane (S632-S633).
C.04.03 Relevance of study design for the effectiveness of long-acting injectable antipsychotics in schizophrenia by C. Correll (S633-S634).
C.04.02 What can we do to improve adherence to treatment in patients with schizophrenia? by F. Cañas (S633).
C.02.01 What is recovery in depression? – The debate by R. McIntyre; D. Meron (S631).
P.8.b.017 Psychiatric comorbidity in diabetes mellitus type 1 and type 2 and the role of personality in glycemic control by O. Karpenko; A. Bobrov; E. Starostina (S628-S629).
P.8.b.013 Suicide survivors with complicated grief (CG): do they differ from other kinds of bereaved individuals with CG? by C. Carmassi; E. Calderani; B. Pocai; S. Gemignani; M. Menichini; C. Manni; P. Scocco; L. Dell'Osso (S626-S627).
P.8.b.012 Sleep disorders in psychiatric patients: a review of the literature by A. Sarrigiannidis; D. Antoniadis; G. Garyfallos (S625-S626).
P.8.b.014 Relationship between spirituality/mysticism/psychoticism, PTSD and suicidality among 475 earthquake survivors by C. Carmassi; P. Stratta; E. Massimetti; M. Corsi; B. Pocai; S. Gemignani; A. Rossi; L. Dell'Osso (S627).
P.8.b.015 Validation of the Italian version of the Inventory of Complicated Grief (ICG) by C. Carmassi; I. Pergentini; E. Calderani; C. Manni; M. Menichini; S. Gemignani; B. Pocai; C. Bertelloni; L. Dell'Osso (S627-S628).
P.8.b.016 Which factors are related to anticipatory nausea/vomiting in breast cancer patients receiving chemotherapy? by Y.W. Bhan; H.Y. Choi; S.I. Kim; W.J. Lim (S628).
C.07.01 Neurobiology of alcohol dependence by A. Lingford-Hughes (S634).
C.07.02 Treatment options for alcohol dependence by W. Van den Brink (S634).
C.17.02 Measuring cognition in animals and humans by T.W. Robbins (S638).
C.17.01 Cognitive dysfunction in major depression: circuits & targets by F. Artigas (S637).
C.17.03 Cognitive effects of antidepressants in clinical studies by M.H. Trivedi (S638).
Author Index (S639-S661).
Keyword Index (S663-S670).
C.12.03 Confronting paradigms of stress, exhaustion and burnout: are we taking this seriously? by D. Edwards (S637).
C.12.02 Shaping the future of anxiety therapy: a new approach for closing the gap between efficacy and safety by H. Volz (S636-S637).
C.08.01 Improving patient outcomes in bipolar disorder by E. Vieta (S635).
C.07.03 Benefits of patient-centred care in alcohol dependence by G.M. Schippers (S634-S635).
C.08.02 A disease for life? Beyond acute episodes in bipolar disorder by G. Goodwin (S635-S636).
C.11.02 The effect of symptoms on functioning and daily life by M. Lambert; P. McGuire; A. Schreiner; S. Galderisi (S636).
C.12.01 Outcome improvements in Alzheimer's disease treatment by S. Gauthier (S636).
P.8.b.011 Cortico-limbic dysfunction in borderline personality disorder: adverse childhood experiences and treatment with clozapine by B. Vai; L. Sforzini; D. Radaelli; S. Poletti; R. Visintini; F. Benedetti (S625).
P.8.b.010 The quality of life of donors following living donor liver transplantation by A. El Missiry; R.E. Hashem; A.H. Khalil; A.M. Omar; M.S. El-Meteini; E.I. Abo El-Ela; M.A. Hamed (S624-S625).
P.7.e.003 Sleep in adolescents: association with emotional problems and suicidal ideation by P. Burón; S. Al-Halabí; E. Díaz-Mesa; M. Garrido; L. García-Álvarez; J.L. Rancaño; M. Casero; P.A.Z. García-Portilla; P.A. Sáiz; J. Bobes Burón; S. Al-Halabí; E. Díaz-Mesa; M. Garrido; L. García-Álvarez; J.L. Rancaño; M. Casero; P.A.Z. García-Portilla; P.A. Sáiz; J. Bobes (S613-S614).
P.7.e.002 Heterozygous Snap25 knockout mice as a potential model for ADHD: stress induction and pharmacological challenge by A. Post; S. Popp; T. Töpner; A. Schmitt; K.P. Lesch; A. Reif (S613).
P.7.f.001 Relationships between psychopathology and quality of life among adolescents: a structural equation modeling approach by D. Stevanovic; O. Atilola; Y.P. Singh Balhara; M. Avicenna; H. Kandemir; P. Vostanis; R. Knez; T. Franic; P. Petrov; Z. Vlaskalic (S614).
P.7.f.002 Association of latrophilin 3 gene polymorphism with behavioral problems in attention-deficit/hyperactivity disorder by K.H. Yook; H.J. Hong; J. Song (S614-S615).
P.7.f.003 Neuropsychological characteristics of children and adolescents at high risk for psychosis and early onset first episode of psychosis by E. De la Serna; G. Sugranyes; I. Baeza; V. Sanchez-Gistau; S. Romero; O. Puig; C. Espelt; M. Dolz; J. Castro-Fornieles (S615-S616).
P.7.e.001 Risk behaviours and psychiatric symptoms among adolescents in European schools by V. Carli; C. Wasserman; M. Sarchiapone; C. Hoven; D. Wasserman (S612-S613).
P.7.d.020 Development and validation of a scale for children and adolescents to assess medication related suicidality by P. Santosh; I. Flamarique; D. Purper-Ouakil; A. Zuddas; C. Arango; A. Sutcliffe; H. Hanna; U. Schulze; J. Castro-Fornieles (S611-S612).
P.7.d.016 Differences in the maintenance of stimulants according to formulation: 1-year follow-up study by J. Hwang; S.J. Lee; B.N. Kim; S.C. Cho (S609).
P.7.d.015 Therapeutic drug monitoring (TDM) of fluoxetine in children and adolescents by M. Koelch; A. Pfalzer; F. Keller; P. Plener; M. Gerlach (S608-S609).
P.7.d.017 Adolescents with schizophrenia spectrum disorders treated with electroconvulsive therapy or pharmacotherapy by I. Flamarique; J. Castro-Fornieles; E. De la Serna; A. Pons; M. Bernardo; I. Baeza (S609-S610).
P.7.d.018 Does pharmacological treatment affect brain neurometabolites in adolescents with obsessive–compulsive disorder? by A.E. Ortiz; A.G. Ortiz; C. Falcon; N. Bargalló; A. Morer; M.T. Plana; M.L. Láizaro (S610).
P.7.d.019 Treatment of cognitive deficits in adolescents with early-onset schizophrenia: a randomised controlled trial of cognitive remediation by O. Puig; R. Penadés; I. Baeza; E. De la Serna; V. Sánchez-Gistau; M. Bernardo; J. Castro-Fornieles (S611).
P.7.f.004 Adolescents presenting with designer drug intoxication in a pediatric toxicology department in Bucharest by C. Petrescu-Ghenea; I. Dobrescu; G.C. Anghel; V.G. Nitescu; D.A. Boghitoiu (S616-S617).
P.7.f.005 Development and initial validation of a suicidality scale for children and adolescents by I. Flamarique; J. Castro-Fornieles; D. Purper-Ouakil; A. Zuddas; C. Arango; A. Sutcliffe; H. Hanna; U. Schulze; P. Santosh (S617).
P.8.b.006 Mental distress and treatment interventions in myocardial infarction patients: gender differences by A. Juskiene; J. Juskenas; G. Kundrotas; A. Podlipskyte; V. Gelziniene; V. Jakumaite; R. Bunevicius (S622-S623).
P.8.b.005 Mismatch of sleep time between subjective perception and objective findings from polysomnography in insomnia patients by H. Kim; K. Bae; S. Kim; J. Kim; I. Shin; J. Yoon (S622).
P.8.b.007 Association between obesity indices and cognitive function in the elderly by S.I. Kim; H.J. Lee; K.W. Yun; Y.C. Kim; W.J. Lim; H.Y. Choi (S623).
P.8.b.008 Sleep disturbance and pain severity: the influence of affective and attentional state by L. Harrison; S. Wilson; M.R. Munafo (S623-S624).
P.8.b.009 Borderline personality disorder significantly improved when treated with 18 mg per day of paliperidone ER: a case report by G. Callista; G. Di Emidio (S624).
P.8.b.004 Feasibility of centralised ratings for mental health safety screening in a dermatology trial by J.B.W. Williams; D. Popp; L.M. Price; J.A. Gross; D. Davis; D. Salvucci; M.J. Detke (S621-S622).
P.8.b.003 Therapist's role of primary health care in the management of patients with mental disorders by M. Kuznetsova (S621).
P.8.a.001 The effect of riboflavin (vitamin B2) on formalin-induced lumbar pain by A. Dondas; I. Chiriac; T. Alexa; A. Luca; D. Negru; C. Bohotin (S618-S619).
P.7.f.006 Gender profile of violent adolescents by E. Serfaty; A. Masautis; L. Florio (S617-S618).
P.8.a.002 Pharmacological effects and toxicity of newly synthesised peptidomimetic compounds by M. Novoselski; E. Encheva; D. Tsekova; R. Klissurov; S. Stoeva; L. Tancheva (S619).
P.8.b.001 The evaluation of emotion recognition in eating disorders by N. Oztürk; B. Yücel (S619-S620).
P.8.b.002 Neuropsychological comorbidity in patients attended in internal medicine departments by J.A. Díaz Peromingo; J. Grandes Ibáñez; J.J. González Soler; M.F. García Suárez; J. Naveiro Soneira; I. Novo Veleiro; A. Fernández Rial; S. Molinos Castro; I. Íñiguez Vázquez; M.J. Domínguez Santalla (S620).
P.6.c.011 The effect of GABA agonists in nucleus accumbens on morphine withdrawal signs in rats by B. Topkara; E. Sakalli; M. Jaferova; H. Yananli (S571).
P.6.c.010 The efffect of agmatine in nucleus accumbens on morphine withdrawal signs in rats by H. Yananli; E. Sakalli; M. Caferova Demirkapu; B. Topkara; E. Mammadov; I.N.A. Dervishi; M. Caglar; O. Uslu; M. Beyatli (S570-S571).
P.4.e.002 Effects of anxiogenic substances on cardiovascular and respiratory functions in conscious rats by V. Castagne; S. Rompion; V. Virley; M. Lemaire (S525-S526).
P.4.e.001 Analysis of the association of several serotoninergic system genes with suicidal behavior in two different populations of Bashkortostan by A. Valiullina; Z. Khalilova; A. Zainullina; E. Khusnutdinova (S525).
P.4.e.003 The tumor supressor down-regulated in renal cell carcinoma 1 gene as a new link between stress, synaptic plasticity and behaviour by M. Masana; Y.A. Su; J. Dine; C. Liebl; K.V. Wagner; M. Eder; M.V. Schmidt; T. Rein; M.B. Müller (S526).
P.4.e.004 Involvement of μ opioid receptors in escape promoted in elevated T maze test by C. Biesdorf; C.M. Roncon; C.B. Almeida; H. Zangrossi; F.G. Graeff; E.A. Audi (S526-S527).
P.4.e.006 Orthorexia among Polish urban youth by M. Stochel; J.H. Joanna Hyrnik; I.J. Ireneusz Jelonek; J.Z. Jan Zejda; M.J.K. Malgorzata Janas-Kozik (S527-S528).
P.4.e.005 Dopaminergic mechanisms of obsessive compulsive spectrum disorders in two pharmacological rat models of dopaminergic dysregulation by M. Voget; F. Wieske; C. Reinel; J. Rummel; J. Klein; I. Puls; C. Winter (S527).
P.4.d.002 Effect of ziprasidone augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder by V. Currò; A. Bruno; G. Pandolfo; G. Scimeca; M.R.A. Muscatello; R.A. Zoccali (S524).
P.4.d.001 General error monitoring system dysfunction in obsessive compulsive disorder patients: an event related potential study by L. Carmi; U. Al-yagon; A. Zangen; R. Dar; J. Zohar (S523-S524).
P.4.c.004 Acute stress selectively affects synaptic vesicle pools in prefrontal cortex glutamatergic terminals: preventing effect of desipramine by N. Nava; M. Popoli; L. Musazzi; G. Wegener; J.R. Nyengaard (S521).
P.4.c.003 Identification of a significant role for the ventral hippocampus in neuropeptide S-elicited anxiolysis by I.A. Ionescu; J. Dine; J. Stepan; Y.C. Yen; F. Holsboer; R. Landgraf; M. Eder; U. Schmidt (S520).
P.4.c.005 Stress and corticosterone increase the readily releasable pool of vesicles in rat synaptosomes of prefrontal/frontal cortex by G. Treccani; L. Musazzi; C. Perego; M. Milanese; T. Bonifacino; J. Lamanna; A. Malgaroli; G. Racagni; G. Bonanno; M. Popoli (S521-S522).
P.4.c.006 Diagnostic and treatment particularities of early-onset obsessive–compulsive disorder in children by A. Simion; M. Mihaela; S. Macovei (S522).
P.4.c.007 Acetyl-l-carnitine prevents the stress-induced chromatin remodeling within the glutamatergic synapse by C. Nasca; T. Rubin; J. Gray; B. Bigio; B.S. McEwen (S522-S523).
P.4.e.007 Perceptions of obsessive compulsive disorder and the impact on treatment outcomes by M. Van Ameringen; W. Simpson; B. Patterson (S528).
P.4.e.008 The use of technology-based communication and the impact on the social functioning of individuals with and without social phobia by M. Van Ameringen; W. Simpson; B. Patterson; J. Turna (S529).
P.4.f.006 Comparison of psoriasis patients with control groups in terms of psychiatric variables by O. Arisoy; C. Karakilic; M. Boztas; H. Kaya; A. Parlak (S534-S535).
P.4.f.005 Aripiprazole in obsessive–compulsive disorder: a case series of 71 patients refractory to other antipsychotics augmentation strategies by C. Segalas; P. Alonso; E. Real; C. López-Solà; M. Estévez; J.M. Menchon (S533-S534).
P.5.a.001 Single amyloid precursor protein (APP) locus knockin mouse models of Alzheimer's disease by T. Saido; T. Saito; Y. Matsuba; N. Yamazaki (S535).
P.5.a.002 Effects of streptozocin-induced diabetes on behaviour in a 5XFAD mouse model of Alzheimer's disease by K. Sonn; A. Zharkovsky (S535-S536).
P.5.a.003 Targeting behavioural and psychological symptoms of dementia: comparison of antipsychotics and the novel compound ADN-1184 in rat models by M. Kolaczkowski; P. Mierzejewski; P. Bienkowski; A. Wesolowska; A. Newman-Tancredi (S536).
P.4.f.004 Deep brain stimulation in obsessive–compulsive disorder induces striatal dopamine release by M. Figee; N.C.C. Vulink; G. Van Wingen; J. Booij; D. Denys (S533).
P.4.f.003 The cumulative effect of multiple childhood trauma on adult depression, PTSD and health-related quality of life by A. Agorastos; L.H. Aversa; J. Pittman; A. Goldsmith; C. Nievergelt; C.J. Hansen; D.G. Baker (S532-S533).
P.4.e.010 Anxiety in mothers of children with thalassemia by Z. Binbay; M. Solmaz; B. Turk Lal; S. Sagir (S530).
P.4.e.009 A translational look at the serotonin transporter and corticotropin-releasing hormone in the acquisition of adaptive fear responses by J.M. Van Gool; J.M.P. Baas; I. Heitland; E.Y. Bijlsma; L. Groenink (S529-S530).
P.4.e.011 Oxytocin in the central nucleus of the amygdala mediates social buffering of fear by E. Rickenbacher; M. Moita (S530-S531).
P.4.f.001 Alexithymia, emotion and quality of life in patients with atypical chest pain by J.H. Kim; S.H. Park; H.C. Lee; Y.M. Jae; S.H. Jang; J.H. Choi (S531).
P.4.f.002 Examining the nature of the comorbidity between pediatric attention-deficit/hyperactivity disorder and posttraumatic stress disorder by J. Biederman (S531-S532).
P.4.c.002 Anxiolytic action of a new 5-HT2A antagonist RU-476 by D.V. Maltsev; D.S. Yakovlev; D.G. Matokhin; Y.V. Samsonik; A.A. Spasov; V.A. Anisimova (S519-S520).
P.4.c.001 Impact of alcohol withdrawal on working memory and brain chromatin remodeling in mice by D. Beracochea; G. Dominguez; M. Dagnas; N. Henkous; N. Mons (S519).
P.4.a.001 Efficacy and tolerability of escitalopram as monotherapy or in combination with mirtazapine in generalized anxiety disorder (GAD) by G. Sulejmanpasic-Arslanagic; S. Fisekovic; S. Ler; A. Frenjo (S507-S508).
P.3.f.026 Could a simplified PANSS be more efficient? by G. Sachs; D. Daniel; J. Dries (S506-S507).
P.4.a.002 Heart rate variability in drug naive panic disorder patients compared with healthy controls by S. Pirildar; G. Sart; M. Kayikcioglu; T. Kose (S508).
P.4.a.003 Negative and biased facial emotion recognition of social anxiety disorder patients by K.S. Oh; S.J. Cho; J.K. SaKong; E.J. Kim; S.W. Lim (S508-S509).
P.4.a.004 Novel object recognition memory and contextual fear extinction is impaired in a chronic stress mouse model of brain–gut axis dysfunction by P.J. Kennedy; C. O'Mahony; G. Clarke; T.G. Dinan; J.F. Cryan (S509).
P.3.f.025 The effect of exercise therapy with motivational intervention in patients with schizophrenia by C.H. Kim; D. Roh; J.G. Chang; H.B. Lee (S506).
P.3.f.024 Increased slow waves in electroencephalogram (EEG) but not daytime sleepiness in schizophrenic patients during antipsychotic treatment by A. Wichniak; L. Okruszek; A. Wierzbicka; E. Waliniowska; K. Czasak; T. Jakubczyk; M. Jarema; W. Jernajczyk (S505-S506).
P.3.f.020 Usefulness of the support by pharmacists of pharmaceutical therapy for schizophrenic patients by J. Uno (S503).
P.3.f.019 Management of depressive symptoms in schizophrenia: a pooled, post hoc analysis from the asenapine development program by D. Castle; J.K.S. Jensen (S502-S503).
P.3.f.021 Dehydroepiandrosterone sulfate and cortisol levels in schizophrenia and bipolar patients by A. Gundogar; C. Korulsan; K.O. Karamustafalioglu (S503-S504).
P.3.f.022 Serum total antioxidant capacity concentrations in paranoid schizophrenia. A case control study by A.L. Morera-Fumero; E. Diaz Mesa; P. Abreu-Gonzalez (S504).
P.3.f.023 Effect of COMT functional polymorphism on bias against disconfirmatory evidence in schizophrenia by M. Buonocore; M. Bosia; M. Bechi; R. Riccaboni; M. Piantanida; E. Smeraldi; R. Cavallaro (S505).
P.4.a.005 Reliability and validity of the Korean version of the combat exposure scale by T.Y. Kim; J.H. Choi; H.G. Chung; H.S. So (S509-S510).
P.4.a.006 Fractional amplitude of low-frequency fluctuations alterations in obsessive–compulsive disorder subtypes by A. Guinea-Izquierdo; I. Martínez-Zalacaín; C. López-Solà; R. Hernàndez-Ribas; M. Subirà; P. Alonso; C. Segalàs; J.M. Menchón; N. Cardoner; C. Soriano-Mas (S510-S511).
P.4.b.009 Threat-induced autonomic dysregulation in panic disorder evidenced by heart rate variability measures by C.T. Lee; S.M. Wang; H.K. Lee; Y.S. Kweon; K.U. Lee (S516-S517).
P.4.b.008 Structural covariance of striatal and limbic regions in obsessive–compulsive disorder by M. Subirà; O.A. Van den Heuvel; M. Cano; S. De Wit; M.Q. Hoexter; T. Nakamae; J.S. Kwon; D. Mataix-Cols; D.J. Stein; C. Soriano-Mas (S516).
P.4.b.010 Course of DSM-IV social anxiety disorders during pregnancy and postpartum by J. Martini; J. Petzoldt; J. Wittich; H.U. Wittchen (S517).
P.4.b.011 Death anxiety in elderly patients with generalized anxiety disorder by A. Kokurcan; E.T. Ozel-Kizil; S. Kirici (S518).
P.4.b.012 Association study between variants in the D4 dopamine receptor gene (DRD4) and measures of severity for obsessive–compulsive disorder by V.F. Goncalves; J.L. Kennedy; M.A. Richter (S518-S519).
P.4.b.007 Relationship between altered cerebral activity and disease severity in obsessive–compulsive disorder: a resting state fMRI study by C.D. Daoun; C.G. Guillevin Carole; H.W. Hammi Wala; G.R. Guillevin Remy; N.J. Jaafari Nemathollah (S515-S516).
P.4.b.006 Objective versus subjective sleep efficiency in apnea and insomnia patients due to generalised anxiety disorder as compared with normals by S. Rosales-Rodriguez; B. Saletu; P. Anderer; G. Gruber; S. Parapatics; G. Dorffner; G.M. Saletu-Zyhlarz (S514-S515).
P.4.b.002 A multi-centre, placebo-controlled, randomised clinical study with Silexan in patients with sub-threshold anxiety by S. Kasper; I.G. Anghelescu; S. Schläfke (S512).
P.4.b.001 Symptom dimensions modulate amygdala activity in obsessive–compulsive disorder by E. Via; N. Cardoner; J. Pujol; P. Alonso; M. López-Solà; E. Real; O. Contreras-Rodríguez; J.M. Menchón; C. Soriano-Mas; B. Harrison (S511-S512).
P.4.b.003 Symptom dimensions and response to deep brain stimulation in obsessive–compulsive disorder by P. Alonso; C. Segalas; E. Real; C. López-Solà; G. Plans; M.A. Aparicio; J.M. Menchon (S512-S513).
P.4.b.004 Fear of dying and fear of guilt: panic disorder/agoraphobia comorbidity in obsessive–compulsive disorder by D.L.C. Costa; J.B. Diniz; Y.A. Ferrão; M.C. Rosario-Campos; E.C. Miguel; R.G. Shavitt; A.R. Torres; L.F. Fontenelle (S513).
P.4.b.005 Hypochondriasis, panic and obsessive–compulsive symptoms: genetic overlap in a twin-based population sample by C. Lopez-Sola; P. Alonso; L.F. Fontenelle; D. Cuadras; J.M. Menchón; B.J. Harrison (S514).
P.5.a.004 Aluminium exposure to adult rats impairs long-term potentiation but not short-term potentiation in the dentate gyrus by B. Tan; B. Karaca; S. Bitiktas; S. Kavraal; H.B. Ulusoy; C. Suer (S537).
P.5.a.005 Effect of cholinesterase inhibitors on cholinergic deficit induced by 3-quinuclidinyl benzilate in rats performing the multiple T-maze by J. Misik; J. Kassa; A. Kracmarova (S537-S538).
P.6.b.004 Efficacy of nalmefene as-needed in alcohol dependent patients with high drinking risk level: subgroup analysis of two studies by W. Van den Brink; H.J. Aubin; A. Bladström; L. Torup; A. Gual; K. Mann (S559-S560).
P.6.b.003 Associations between drinking behavior and other unhealthy habits by H.N. Kim; S.H. Kim; S.W. Song (S559).
P.6.b.005 Long-term efficacy of nalmefene as-needed in alcohol dependent patients with high drinking risk level: results of a subgroup analysis by K. Mann; P. Sørensen; L. Torup; W. Van den Brink; A. Gual (S560).
P.6.b.006 Differences in depression according to history of suicide attempts among inpatients with depression and acute alcohol intoxification by D.W. Shin (S560-S561).
P.6.b.007 Clinical relevance of nalmefene in the treatment of alcohol dependence: subgroup analysis of patients with high drinking risk level by D. Nutt; P. Sorensen; L. Torup; C. Francois; H.J. Aubin (S561-S562).
P.6.b.002 Salivary cortisol responses to psychological stress in Korean social drinkers with a family history of alcoholism by S.G. Kim; Y.N. Seo; H.C. Kim; S.Y. Kim; J.G. Kim (S558-S559).
P.6.b.001 As-needed use of nalmefene in the treatment of alcohol dependence: subgroup analysis of patients with high drinking risk level by J.M.A. Sinclair; J. Chick; P. Sørensen; A. Gual (S558).
P.6.a.006 Deletion of cannabinoid CB2 receptor increases the reinforcing and motivational actions of ethanol by F. Navarrete Rueda; A. Ortega-Álvaro; A. Ternianov; A. Aracil-Fernández; M.S. García-Gutiérrez; J. Manzanares (S555-S556).
P.6.a.005 Density of thrombocyte benzodiazepine receptors and levels of neuroactive steroid hormones in alcoholic patients by T. Shushpanova; N. Bokhan; T. Novozheyeva (S555).
P.6.a.007 Low dose maternal nicotine and alcohol exposure disrupt hippocampal long-term potentiation and Morris water maze performance in the offsprings by S. Bitiktas; D. Timur; S.K. Oncu; S. Kavraal; T. Gunes; A. Golgeli; C. Suer (S556).
P.6.a.008 Neuropeptide S receptor gene variant and stressful life events: associations with alcohol use disorder and alcohol consumption by K. Laas; A. Reif; K. Akkermann; E. Kiive; K. Domschke; K.P. Lesch; T. Veidebaum; J. Harro (S557).
P.6.a.009 Effects of early life stress on adolescent alcohol consumption; interactions with withdrawal and restraint stress by M.P. Viveros; S. Peñasco; E.M. Marco (S557-S558).
P.6.b.008 Association of family history of alcoholism, scores of CAGE, AUDIT and DSM-IV diagnostic criteria in alcohol-dependent patients by J.S. Yi; S.H. Lee; I.G. Choi (S562).
P.6.b.009 Changes of DNA methylation of the HERP gene promoter and its mRNA expression during alcohol detoxification by B.H. Lee; M.R. Choi; Y.G. Chai; J.S. Lee (S562-S563).
P.6.c.006 Cue-reactivity in prolonged, frequent cannabis use: a three year follow-up study by W.A.M. Vingerhoets; L. Koenders; J. Cousijn; T.A.M.J. Van Amelsvoort (S568).
P.6.c.005 Exposure to caffeine and sucrose changes locomotor behaviour, neurobiology and response to acute methamphetamine challenge by J.L. Franklin; M. Mirzaei; M.K. Sauer; T.A. Wearne; A.K. Goodchild; P.A. Haynes; J.L. Cornish (S567-S568).
P.6.c.007 Deletion or blockade of cannabinoid CB2 receptors modifies the reinforcing, motivational and physiological actions of nicotine in mice by F. Navarrete Rueda; M. Rodríguez-Arias; E. Martín-García; D. Navarro; M.S. García-Gutiérrez; A. Aracil-Fernández; P. Berbel; J. Miñarro; R. Maldonado; J. Manzanares (S568-S569).
P.6.c.008 Deep brain stimulation of the nucleus accumbens core affects heroin seeking and impulsivity in rats by M.C. Schippers; M. Gaastra; T. Mesman; Y. Van Mourik; D. Schetters; A.N.M. Schoffelmeer; T. Pattij; T.J. De Vries (S569-S570).
P.6.c.009 The effect of paroxetine on intravenous self-administration of methamphetamine in an animal model of depression by Z. Miklosova; J. Kucerova; P. Amchova; A. Sulcova (S570).
P.6.c.004 Transdermal cannabidiol: long-lasting attenuation of relapse vulnerability in animal models of drug seeking, anxiety, and impulsivity by F. Weiss; G. Gonzales-Cuevas; A.L. Stinchcomb (S567).
P.6.c.003 Environmental, genetic and epigenetic components in drug abuse and relapse to drug seeking by V. Carola; L. Lo Iacono; F. Visco Comandini; M.G. Alari; R. Furfaro; P. Caputo; S. Cabib; S. Puglisi-Allegra (S566).
P.6.b.011 Attentional bias and inhibitory behavioural changes in patients with alcohol dependence and bipolar disorders treated with aripiprazole by G. Rubio; R. Jurado-Barba; I. Martinez-Gras; G. Ponce; R. Rodriguez-Jimenez; I. Colado; J. Manzanares (S563-S564).
P.6.b.010 Virtual reality therapy decreased metabolism of lentiform nucleus in patients with alcohol dependence: PET study by S. Ji Hyun; H. Doug Hyun; N. Churl; L. Sang Hoon; S. Ju Won (S563).
P.6.b.012 Management of affective disorders in alcohol-dependent patients by A. Bandati; A.O. Bandati; A. Albu (S564-S565).
P.6.c.001 Cannabis use is associated with biological markers of ageing in healthy volunteers by L. Scoriels; S. Theegala; M. Giro; S.E. Ozanne; K. Burling; P.B. Jones; E. Fernandez-Egea (S565).
P.6.c.002 A dipeptide analog of neurotensine (8–13) with mild analgesic activity significantly decreases opiate withdrawal signs in rats by M.A. Konstantinopolsky; I.V. Chernyakova; L.G. Kolik; V.S. Kudrin; P.M. Klodt; T.A. Gudasheva (S565-S566).
P.6.a.004 Long-lasting brain activation induced by voluntary alcohol drinking in rats assessed with manganese-enhanced magnetic resonance imaging by L. Dokleja; M. Dudek; U. Abo-Ramadan; P. Hyytiä (S554-S555).
P.6.a.003 Spironolactone suppresses ethanol-seeking behavior and relapse in rats by V. Kashkin; E. Shekunova; Y. Bagrov; A. Bagrov (S553-S554).
P.5.b.006 Assessment of adiponectin and its isoforms in elderly women with late onset Alzheimer's disease and mild cognitive impairment by W. Bik; A. Baranowska-Bik; E. Wolinska-Witort; M. Kalisz; M. Styczynska; M. Chodakowska-Zebrowska; A. Pfeffer-Baczuk; M. Barcikowska; B. Baranowska (S542-S543).
P.5.b.005 Estimation of the effect of drug treatment for Alzheimer-type dementia with behavioural and psychological symptoms of dementia (BPSD) by M. Fujita; T. Ishizuka (S542).
P.5.b.007 Inter-rater reliability of structural imaging assessment with visual rating scales in patients with Alzheimer's disease by B. Colak; O. Er; A. Kokurcan; U. Altunoz; E.T. Ozel-Kizil (S543-S544).
P.5.b.008 Are there differential neuropsychological profiles in mild cognitive impairment patients with depressive symptoms? by M. Signorelli; E. Aguglia; F. Caraci; S. Castellano; S. Di Nuovo; A. Ullo (S544).
P.5.c.001 An experimental study of the effects of rivastigmine and memantine alone and in combination on learning and memory in rats by P. Yanev; D. Dimitrova; D. Getova (S544-S545).
P.5.b.004 Object pattern separation performance in Alzheimer's patients links compromised hippocampal neurogenesis to APOE4 status and CSF Aβ42 by K. Wesnes (S541-S542).
P.5.b.003 Yokukansan in the treatment of behavioural and psychological symptoms of dementia by Y. Matsuda; T. Kishi; H. Shibayama; N. Iwata (S541).
P.5.a.007 Sphingosine-1-phosphate: from regulation of gene expression to cytoprotection in an experimental model of neurodegenerative disorders by J.B. Strosznajder; J. Pyszko; K. Czubowicz; R.P. Strosznajder (S538-S539).
P.5.a.006 The effect of intracerebroventricular administration of (25–35)-β-amyloid fragment on EEG and cognition in the rat – a pilot study by L. Kaderabek; T. Palenicek; E. Lhotkova; F. Tyls; A. Kubesova; M. Fujakova; H. Tejkalova; V. Krajca (S538).
P.5.a.008 Effects of clinically approved, pro-cognitive pharmacological agents on electroencephalography in Alzheimer's disease-model mice by J. Kelley; L. Raeymaekers; A. Ahnaou; C. Babiloni; C. Czech; S. Dix; J.C. Richardson; E. Schenker; X. Langlois; W. Drinkenburg (S539).
P.5.b.001 Clinical characteristics and cognitive functions of late-onset psychoses: a case–control study by S. ElGhonemy; H. Sadek; R. Bassim; M. Soltan; D. El Serfei (S540).
P.5.b.002 Association between sirtuin 2 gene rs10410544 polymorphism and depression in Alzheimer's disease in two independent European samples by S. Porcelli; R. Salfi; A. Politis; A.R. Atti; D. Albani; L. Lia; G.N. Papadimitriou; D. De Ronchi; A. Serretti (S540-S541).
P.5.c.002 Nanoparticles as disease-modifying mediators for brain therapy: focus on Huntington's disease by B.M.D.C. Godinho; J.R. Ogier; R. Darcy; C.M. O'Driscoll; J.F. Cryan (S545).
P.5.d.001 Sleep problems in patients with Parkinson's disease in a hospital setting from Romania by M.M. Dumitru; V. Chirita; R. Chirita (S546).
P.5.f.002 Consensus and variations in opinions on delirium care: a survey of the European Delirium Association by D. Meagher; A. Morandi; D. Davis; J. Taylor; G. Bellelli; B. Olofsson; S. Kreisel (S551-S552).
P.5.f.001 Correlations between pain intensity and cognitive dysfunction in surgery by O. Marcoci; A.L. Chirita (S550-S551).
P.5.f.003 Variables influencing treatment adherence in patients with Alzheimer's disease by S.H. Kim (S552).
P.6.a.001 Ghrelin and steroid hormones in serum of chronically alcoholised rats by P. Khokhlov; E.R. Bychkov; A.A. Lebedev; P.D. Shabanov (S552-S553).
P.6.a.002 Internal and test–retest reliability of the modified Stroop and the disengagement task by A. Ataya; S. Adams; A.S. Attwood; M.R. Munafò (S553).
P.5.e.001 The influence of aggregated (25–35)-β-amyloid fragment on cell proliferation and microglial activation in the rat hippocampus by A. Kubesova; M. Fiser; F. Tyls; L. Kaderabek; T. Palenicek (S550).
P.5.d.007 Vivid dreams, hallucinations and psychosis in Guillain-Barre syndrome – case presentation by C. Crisan; I. Miclutia; O. Vanta; L. Perju-Dumbrava (S549-S550).
P.5.d.003 First- and second-line pharmacological treatment for delirium – retrospective analysis in a general hospital setting by K. Wada; Y. Morita; T. Iwamoto; Y. Mifune; Y. Aihara; S. Nojima (S547).
P.5.d.002 Cannabidiol add-on usual treatment improves the outcome of patients with Parkinson's disease by M.H.N. Chagas; V. Tumas; M. Penna-Pereira; M. Sobreira-Neto; E.T. Sobreira; A.L. Eckeli; J.E.C. Hallak; A.C. Dos Santos; J.A.S. Crippa; A.W. Zuardi (S546-S547).
P.5.d.004 Skin-picking heralding Parkinson's disease by K.Y. Chee; A.H. Evans; D. Velakoulis (S547-S548).
P.5.d.005 Reduced dopamine transporter binding predates impulse control disorders in Parkinson's disease by O.A. Van den Heuvel; C. Vriend; A.H. Nordbeck; J. Booij; Y.D. Van der Werf; T. Pattij; P. Voorn; P. Raijmakers; E. Van de Giessen; H.W. Berendse (S548-S549).
P.5.d.006 Dopaminergic dysregulation syndrome in Parkinson's disease: management in a psychiatric unit of a general hospital by A. Pérez Vigil; A. Fàbrega Ribera; R. Martin-Santos Laffon; A. Pons Villanueva (S549).
P.2.c.011 Overexpression of the homeobox Otx2 gene leads to spontaneous fluctuations in manic- and depressive-like behaviour by M. Jukic; A. Avin; M. Bar; T. Baron; K. Zega; O. Novikov; O. Kofman; G. Agam; C. Brodski (S360-S361).
P.2.c.010 The inflammatory genetic background and genetically disruption of lithium related molecular pathways in bipolar disorder patients by C. Crisafulli; A. Drago; A. Serretti (S360).
P.1.b.001 Neural correlates of stressful life events at onset of obsessive-compulsive disorder by E. Real; C. Orfila; P. Alonso; C. Segalàs; J. Labad; M. Subirà; M. Pinillos; N. Cardoner; J.M. Menchón; C. Soriano-Mas (S174-S175).
P.1.a.026 Different regulation of endogenous neuropeptides gene expression in resistance to diet-induced obesity by M. Pucci; M.V. Micioni Di Bonaventura; R. Ciccocioppo; M. Maccarrone; C. Cifani; C. D'Addario (S174).
P.1.b.002 Event-related potentials in first-episode schizophrenia patients: relationship with clinical data and psychopharmacotherapy by O. Lykholetova; V. Abramov; B. Ivnev; A. Snegir (S175-S176).
P.1.b.003 Differences in the number and distribution of hypothalamic dopaminergic cells in rats after novelty test by K. Plucinska; G. Jerzemowska; J. Orzel-Gryglewska (S176).
P.1.b.005 A diminished mismatch negativity response in misophonia, a potential marker for aggressive impulsivity by A.E. Schroder; A. Mazaheri; D. Petropoulos; V. Soto; R. Smolders; N.C.C. Vulink; D. Denys (S177).
P.1.b.004 Functional characterisation of human induced pluripotent stem cell-derived neurons in Gaucher's disease by M. Gaval-Cruz; O. Awad; P. O'Donnell; R. Feldman (S176-S177).
P.1.a.025 Age at onset of depressive disorder is associated with interaction of BDNF rs6265 and 5-HTTLPR polymorphism by K. Lee; E.J. Joo; E.J. Kim (S173-S174).
P.1.a.024 Effect of a functional polymorphism of EAAT1 on cognitive impairment in bipolar disorder by G. Sferrazza Papa; S. Poletti; S. Dalla Spezia; C. Locatelli; C. Colombo; F. Benedetti (S173).
P.1.a.020 Pharmacogenetic response to antidepressant and suicidality in a large cohort of outpatients with a major depression episode by N. Ramoz; Y. Le Strat; P. Courtet; P. Gorwood (S171).
P.1.a.019 Association of glucocorticoid receptor gene NR3C1 polymorphisms and schizophrenia in a Korean population by Y. Kim; W.S. Kang; J.W. Kim; A.R. Cho (S170-S171).
P.1.a.021 A molecular pathway analysis of the genes in 22q11.2 provides information on the genetic structure of psychosis by A. Drago; C. Crisafulli; D. De Ronchi; A. Serretti (S171-S172).
P.1.a.022 Role of phospholipases in response to treatment. Data from the STEP-BD study by M. Balestri; A. Drago; D. De Ronchi; A. Serretti (S172).
P.1.a.023 NRG1 and DISCI gene polymorphisms with respect to cognitive endophenotype in schizophrenia by D. Frydecka; A. Kiejna; M. Szewczuk-Boguslawska; A. Beszlej; E. Pawlak-Adamska; L. Karabon; A. Partyka; A. Tomkiewicz (S172-S173).
P.1.b.006 Auditory P300 in euthymic patients with bipolar disorder by N. Custal; E. Cerrillo; M. Veciana; J. Pedro; J. Montero; J.M. Crespo; J.M. Menchón (S177-S178).
P.1.b.007 Detailed anatomical mapping of ‘neuropeptide S’ expressing cell populations in the human brainstem by C. Adori; S. Barde; G.G. Kovacs; N. Bogdanovic; M. Palkovits; T. Hökfelt (S178).
P.1.e.004 Sex-hormone fluctuation triggers subclinical depressive symptoms and affects immune cell numbers in peripheral blood in healthy women by M. Heede; H. Søndergaard; A. Pinborg; K. Christensen; H. Ullum; F. Sellebjerg; G. Knudsen; V. Frokjaer (S183-S184).
P.1.e.003 Evidence for nongenomic modulation of synaptic plasticity by L-thyroxine in the hippocampus by S. Bitiktas; K. Sehrazat; B. Tan; H. Ornek; K. Ozdogan; N. Dursun; C. Suer (S183).
P.1.e.005 Alterations of cortisol awakening response and DHEA in postpartum depression by H.S. Suh; R.S. Ahn; C.H. Kim; Y.K. Kim (S184-S185).
P.1.f.001 Drug repositioning of anti-inflammatory drugs in major psychiatric disorders by G. Fond; N. Hamdani; M. Leboyer (S185).
P.1.f.002 Suicide attempts and oxidative stress: is there a link? by M. Martin Subero; H. Odebrecht Vargas; S. Odebrecht Vargas Nunes; D. Sabbatini Barbosa; M. Mendonça Vargas; K. Venugopal; M. Berk; M. Maes (S185-S186).
P.1.e.002 Sex-dependent effects of chronic L-thyroxine treatment in the water maze by B. Tan; S. Bitiktas; S. Kavraal; B. Kandemir; I.A. Kurnaz; C. Suer (S182-S183).
P.1.e.001 The clinical utility and cost effectiveness of routine thyroid screening in adult psychiatric patients by R. Schoeman; A. Lachman; K.J. Cloete; M. Kidd (S182).
P.1.b.009 Switching in bipolar disorder: the role of 3H-imipramine, 3H-paroxetine and 5-HT2 binding sites by E. Cerrillo; N. Custal; S. Morchón; P. Rosel; M. Urretavizcaya; J.M. Menchón; J.M. Crespo (S179-S180).
P.1.b.008 Impaired sleep continuity after intracerebroventricularly administered nesfatin-1 in rats by B. Horváth; S. Vas; K. Könczöl; C. Ádori; L. Kalmár; D. Pap; D. Kostyalik; R.S. Papp; Z.E. Tóth; G. Bagdy (S179).
P.1.b.010 Expectation of tactile events and body ownership in schizophrenia: pharmacological correlates by F. Ferri; M. Costantini; A. Salone; G. Di Iorio; A. Chiarelli; A. Merla; G. Martinotti; M. Di Giannantonio; V. Gallese (S180).
P.1.c.001 Cognitive impairment in children – candidate endophenotypes for schizophrenia by I. Sacuiu; A. Burlea-Ciubara; V. Chirita; R. Chirita (S180-S181).
P.1.C.002 Clinical and therapeutic correlates of neurological soft signs in first-episode psychosis by A. Mhalla; L. Gassab; A. Mechri; L. Gaha (S181-S182).
P.1.a.018 The role of gene-environment (G×E), haplotypic and main effect of argininevasopressin and oxytocin receptor genes in personality traits by Y. Kutlumbetova; A. Kazantseva; S. Malykh; E. Khusnutdinova (S170).
P.1.a.017 S-Adenosyl-methionine impairs forced swimming-induced behavioural immobility by inhibiting gene expression in dentate gyrus neurons by E.A. Saunderson; A.F. Trollope; M. Gutièrrez-Mecinas; A.A. Shaikh; H. Spiers; J. Mill; J.M.H.M. Reul (S169).
E.07.01 Effects of psychotropic drugs (psychostimulants, antidepressants) on the immature brain – what are consequences for the adult life? by L. Reneman (S157).
E.06.02 Substance use disorders and depression by M. Torrens (S157).
E.07.02 Clinical use of psychotropic drugs in youth – interests and pitfalls by C. Arango (S157-S158).
P.1.a.001 Monoamine oxidase A DNA hypomethylation predicts impaired treatment response in depression by K. Domschke; N. Tidow; K. Schwarte; J. Deckert; V. Arolt; P. Zwanzger; B.T. Baune (S159).
P.1.a.002 Associations between ARLTL markers and symptoms dimensions in bipolar affective disorder by M. Maciukiewicz; M. Dmitrzak-Weglarz; P.M. Czerski; A. Leszczynska-Rodziewicz; P. Kapelski; A. Szczepankiewicz; M. Skibinska; J. Pawlak; J. Hauser; W.M. Karlowski (S159-S160).
E.05.03 EPA Guidance and the future of European psychiatry by W. Gaebel (S156-S157).
E.05.02 European Psychiatric Association (EPA) guidance on suicide treatment and prevention by D. Wasserman; V. Carli (S156).
E.02.01 Cognitive behaviour therapy in psychosis by M. Van der Gaag; C. De Roos (S155).
S.28.04 New pharmacological treatment strategies targeting GABAergic dysfunction in schizophrenia by C.H. Vinkers (S153-S154).
E.02.02 Trauma treatment in patients with a psychosis by C. De Roos; P. Van der Gaag (S155).
E.03.01 Obesity: a treatable brain disease? by A. Gearhardt (S155-S156).
E.03.02 Obesity and the brain: how convincing is the addiction model? by H. Ziauddeen; I.S. Farooqi; P.C. Fletcher (S156).
P.1.a.003 TNF-alpha −308 G>A polymorphism is associated with suicide attempt in major depressive disorder by Y.K. Kim; J.P. Hong; K.S. Na; S.W. Han; B.H. Lee; H.Y. Jung (S160-S161).
P.1.a.004 The identification of Ptpn1 in hippocampal modulation of food anticipatory behavior by E. Kostrzewa; L.A.W. Verhagen; C. Gelegen; H.A. Van Lith; D.A. Collier; M. Mitsogiannis; E. De Vries; M. Van Gestel; R.A. Adan; M.J.H. Kas (S161).
P.1.a.013 5-HTT is associated with the endophenotype psychological flexibility: preliminary results from a randomised clinical trial by A. Gloster; H.U. Wittchen; J. Deckert; A. Reif (S166-S167).
P.1.a.012 Association between dysbindin gene and cerebral structures in a Spanish population by N. Varela; I. Mata; R. Ayesa; R. Roiz; B. Crespo-Facorro (S166).
P.1.a.014 Expression studies of GTP-binding protein D-Ras2 (DIRAS2), a candidate gene for ADHD by L. Weissflog; E.T. Landaas; A. Camphausen; K.P. Lesch; A. Reif (S167).
P.1.a.015 No interaction of the 5-HTTLPR genetic polymorphism on body image dissatisfaction by neuroticism in a young adult Korean population by I.S. Chee; S.K. Wang; J.L. Kim; Y.H. Lee (S167-S168).
P.1.a.016 CHL1 gene: a new promising antidepressant response marker in major depression by C. Fabbri; D. Gurwitz; J. Stingl; C. Crisafulli; E. Spina; S. Kasper; J. Zohar; D. Souery; J. Mendlewicz; A. Serretti (S168-S169).
P.1.a.011 Lipopolysaccharide (LPS) induced histone modification in the rat brain: implications for psychiatric disease by G. Rigillo (S165-S166).
P.1.a.010 DNA methylation of the BDNF gene in schizophrenia by L. Carlberg; J. Scheibelreiter; M.R. Hassler; M. Schloeglhofer; M. Schmoeger; B. Ludwig; S. Kasper; H. Aschauer; G. Egger; A. Schosser (S165).
P.1.a.006 Single nucleotide polymorphisms and clozapine response in Korean schizophrenic patients who are refractory or intolerant to conventional antipsychotic agents by H.G. Kim; T.H. Kim; H.J. Eun (S162).
P.1.a.005 Association study of corticotropin-releasing hormone receptor 1 (CRHR1) gene polymorphism in Korean alcohol-dependent patients by S.G. Kim; C.M. Kim; H.C. Kim; H.K. Kim; J.G. Kim (S161-S162).
P.1.a.007 FKBP5 single markers and haplotypes predispose to major depressive disorder in Polish patients by B. Narozna; A. Szczepankiewicz; A. Leszczynska-Rodziewicz; J. Pawlak; M. Wilkosc; A. Rajewska-Rager; M. Maciukiewicz; J. Twarowska-Hauser (S163).
P.1.a.008 Increased DNA methylation of the prodynorphin gene promoter in peripheral blood mononuclear cells from patients with bipolar disorder by A. Di Francesco; B. Dell'Osso; M.C. Palazzo; B. Benatti; D. Galimberti; B. Arosio; A.C. Altamura; M. Maccarrone; C. D'Addario (S163-S164).
P.1.a.009 The SNP rs2883187 of brain-derived neurotrophic factor (BDNF) is associated with symptom severity in obsessive-compulsive disorder by R. Tukel; B. Ozata; N. Ozturk; B. Aslantas Ertekin; E. Ertekin; G. Saruhan Direskeneli (S164-S165).
P.1.f.003 Pro-inflammatory cytokines induce anhedonia in mice and increase monoamine transporter activity in the nucleus accumbens by F. Van Heesch; J. Prins; K.G.C. Westphal; G.A.H. Korte-Bouws; B. Olivier; A.D. Kraneveld; S.M. Korte (S186).
P.1.f.004 Mirtazapine-induced serious acute thrombocytopenia by M. Stuhec (S186-S187).
P.1.g.035 The role of P-glycoprotein in central sedative effects of H1-antihistamines by S. Conen; E.L. Theunissen; A. Vermeeren; M. Mehta; J.G. Ramaekers (S209).
P.1.g.034 Effect of lisdexamfetamine in a rat model of binge-eating disorder by D. Heal; S. Vickers; D. Hackett; P. Hutson (S208-S209).
P.1.g.036 Role of cannabinoid CB1 receptor in the regulation of aggressive social behaviour by M. Rodríguez-Arias; F. Navarrete Rueda; M. Daza-Losada; D. Navarro; M.A. Aguilar; P. Berbel; J. Miñarro; J. Manzanares (S209-S210).
P.1.g.037 Methylphenidate, but not antipsychotics, improves prepulse inhibition deficits displayed by CB1 knockout mice by F. Navarrete Rueda; A. Ortega-Álvaro; A. Aracil-Fernández; A. Ternianov; J. Manzanares (S210).
P.1.g.039 Behavioural and neurochemical evidence for implication of the cannabinoid CB1 receptor in the effects of d-amphetamine by A. Polissidis; A. Galanopoulos; O. Chouliara; Z. Papadopoulou-Daifoti; K. Antoniou (S211-S212).
P.1.g.038 Evaluation of the effects of gamma-carboline derivatives on the brain mitochondria by D. Vinogradova; E.F. Shevtsova; S.O. Bachurin (S211).
P.1.g.033 Effects of anandamide on panic-like elaborated escape behavior evoked by GABAA receptor blockade in the ventromedial hypothalamus by T.A. Garcia; R.L. De Freitas; N.C. Coimbra (S207-S208).
P.1.g.032 Metabolic effects of lisdexamfetamine in a rat model of human obesity with insulin resistance by D. Heal; S. Vickers; D. Hackett; P. Hutson (S207).
P.1.g.028 Vilazodone exhibits a favorable sexual profile in male rats by R.S. Oosting; J. Chan; B. Olivier; P. Banerjee (S205).
P.1.g.027 Antidepressant-like effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline in a reserpine model of depression in rat by J. Michaluk; E. Mozdzen; A. Wasik; I. Romanska; L. Antkiewicz-Michaluk (S204-S205).
P.1.g.029 Opioid and GABAergic pathways interactions modulate panic-like behaviours organised by the superior colliculus by J.A. Da Silva; N.C. Coimbra (S205-S206).
P.1.g.030 Evaluation of trazodone sleep–wake profile in the rat by B. Garrone; L. Durando; E. Esneault; D. Virley; S. Tongiani (S206).
P.1.g.031 Functional coupling of group II metabotropic glutamate receptors to Gα-proteins in postmortem frontal cortex of schizophrenic subjects by A. García-Bea; P. Miranda-Azpiazu; R. Díez-Alarcia; A.M. Gabilondo; B. Morentín; J. González-Maeso; J.J. Meana (S206-S207).
P.1.g.040 Role of cannabinoid CB1 receptors in modulation of dopamine output in the prefrontal cortex associated with food restriction in rats by V. Licheri; G. Talani; L. Dazzi; F. Biggio; C. Utzeri; V. Lallai; S. Lutzu; G. Biggio; E. Sanna (S212).
P.1.g.041 Cannabinoid-induced actomyosin contractility leads both to rapid and lasting changes in neuronal morphology by A. Roland; D. Carrel; A. Ricobaraza; B.M. Jordan; F. Rico; A. Simon; M. Humbert-Claude; S. Scheuring; Z. Lenkei (S213).
P.1.g.050 Antidepressant-like effect of celecoxib and piroxicam in rat models of depression by M. Vital; R.M. Santiago; J.K. Barbiero; B.J. Martynhak; S.L. Boschen; L.M. Silva; M.F. Werner; C. Da Cunha; M.M.S. Lima; R. Andreatini (S218).
P.1.g.049 Does the peroxisome proliferator-activated receptor (PPAR)-alpha agonist fenofibrate protect against dopaminergic neuronal death in a rat model of Parkinson's disease? by J.K. Barbiero; R.M. Santiago; F.S. Tonin; S. Boschen; L. Motta; M.F. Werner; C. Da Cunha; M.M.S. Lima; M. Vital (S217-S218).
P.1.g.051 Neuroprotective effect of ibuprofen in a rat model of Parkinsonism induced by prolonged administration with rotenone by T. Zaminelli; R.W. Gradowski; T.B. Bassani; J.K. Barbiero; R.M. Santiago; M. Vital (S219).
P.1.g.052 Understanding blood-brain barrier penetration and link to target engagement by V. Sinha; I. Loryan; P. De Boer; X. Langlois; C. Mackie; A. Van Peer; W. Drinkenburg; A. Vermeulen; D. Heald; M. Hammarlund-Udenaes (S219-S220).
P.1.g.053 Role of acetylcholine-mediated neurotransmission within nucleus raphe magnus in the post-ictal antinociception by R.C. De Oliveira; T. Paschoalin-Maurin; R. De Oliveira; N.C. Coimbra (S220).
P.1.g.048 Antidepressant-like effect of melatonin in a rat model of Parkinson's disease induced by rotenone by T.B. Bassani; R.W. Gradowski; T. Zaminelli; J.K. Barbiero; R.M. Santiago; M. Vital (S217).
P.1.g.047 The effect of cannabis on memory function in users with and without a psychotic disorder: a meta-analysis by T. Schoeler; J. Kambeitz; S. Bhattacharyya (S216-S217).
P.1.g.043 Psychopharmacological treatment in heart transplantation candidates by R. Sánchez González; J.M. Peri; E. Baillés; A. Bastidas; F. Pérez-Villa; A. Bulbena; L. Pintor Pérez (S214).
P.1.g.042 A study on the effects of psychotropic drug use during pregnancy on fetal development in female patients with psychiatric disorders by Y. Chung; E. Lee; J. Noh (S213-S214).
P.1.g.044 Effects of pharmacologically induced sex-hormone fluctuations on emotional processing of faces in healthy women by S. Henningsson; K.H. Madsen; A. Pinborg; M. Heede; G.M. Knudsen; H.R. Siebner; V.G. Frokjaer (S214-S215).
P.1.g.045 Neuroprotective effect of the monoacylglycerol lipase inhibitor JZL184 in a parkinsonian mouse model by M. Celorrio; D. Fernández-Suárez; R. Franco; M.S. Aymerich (S215).
P.1.g.046 Activation of 5-HT1A and 5-HT2A/2C receptor in the dorsomedial hypothalamus attenuates escape behaviour by A. Biagioni; R.C. De Oliveira; H.J. Zangrossi; N.C. Coimbra (S216).
P.1.g.026 Neuroprotective tetrahydroisoquinoline alkaloids have antidepressant-like effects in the clonidine model of depression by L. Antkiewicz-Michaluk; I. Romanska Irena; A. Wasik; E. Mozdzen; J. Michaluk (S203-S204).
P.1.g.025 N-Acetyl cysteine as a potential tobacco use cessation agent in bipolar disorder and schizophrenia by M. Rapado-Castro; S. Dodd; O. Dean; Z.X. On; A.I. Bush; M. Berk (S203).
P.1.g.007 Low performing rats model for the inattentive subtype of adult ADHD in the 5-choice continuous performance task (5C-CPT) by A. Tomlinson; K.M. Marshall; J.C. Neill (S192).
P.1.g.006 Neuroprotective and neurogenic effects of haloperidol and risperidone in the ischemic hippocampus by D.H. Kim; Y.S. Moon; B.K. Son (S191-S192).
P.1.g.008 Sub-anesthetic ketamine modulates intrinsic BOLD connectivity between the hippocampus and the prefrontal cortex in the rat by N. Gass; A.J. Schwarz; A. Sartorius; E. Schenker; C. Risterucci; M. Spedding; L. Zheng; A. Meyer-Lindenberg; W. Weber-Fahr (S192-S193).
P.1.g.009 Serotonin transporter binding is increased by a gonadotropin-releasing hormone agonist in female rats by A. Overgaard; M.E.K. Lie; C.V. Jorgensen; J.D. Mikkelsen; G.M. Knudsen; V.G. Frokjaer (S193-S194).
P.1.g.010 The effects of the atypical antipsychotics aripiprazole and olanzapine on learning and memory in naïve rats by M. Topolov; D. Getova (S194).
P.1.g.005 Study of the effects of ketamine and gabapentin on two convulsive tests in mice by N. Doncheva; D. Getova (S191).
P.1.g.004 Influence of ABCB-1 genotype on spontaneous sleep and sleep-EEG changes after escitalopram in healthy volunteers by A. Steiger; M. Kluge; M. Dresler; B. Wollweber; A. Yassouridis; M. Uhr (S190-S191).
P.1.f.006 Functional reorganisation of the mesolimbic system after its terminal area destruction influences blood T lymphocytes and their subsets by K. Plucinska; B. Grembecka; W. Glac; D. Myslinska; G. Jerzemowska; P. Badtke; D. Wrona (S188).
P.1.f.005 Immune response correlates with behavioral activity, associated with memory processes following chronic stimulation of the medial septum by M. Podlacha; D. Myslinska; D. Wrona (S187-S188).
P.1.f.007 Effects of the administration of lipopolysaccharide and a murine T-lymphoma cell line on brain activation and immune function in male Wistar rats by K. Plucinska; T. Cecot; I. Majkutewicz; Z. Ciepielewski; K. Ptaszek; D. Myslinska (S188-S189).
P.1.g.001 Effects of carvedilol on the social behavior of rats submitted to an animal model of mania by B.M.M. Ribeiro; G.C. Souza; A.I.G. Queiroz; J.A.S. Gomes; L.M. Cavalcante; M.J.S. Machado; M.M. Araujo; R.C. Cordeiro; A.F. Carvalho; D.S. Macedo (S189).
P.1.g.003 Rivastigmine causes antidepressant, anxiolytic and procognitive effects in the chronic mild stress model in rats by M. Papp; P. Gruca; M. Lason-Tyburkiewicz (S190).
P.1.g.011 Effect of chronic fluoxetine treatment on subthalamic nucleus and catalepsy in the rat by L. Ugedo; T. Morera-Herreras; J.A. Ruiz-Ortega; I. Vidaurrazaga; C. Miguelez; A. Aristieta (S194-S195).
P.1.g.012 The CB2 ligand AM630 (6-iodopravadoline) increases the content and activity of pro-apoptotic markers in mouse brain by M. Álvaro-Bartolomé; G. Salort; J.A. García-Sevilla (S195).
P.1.g.021 Dissociation of mGlu2/3 agonist effects on global and task related ketamine oxygen signals: the quest for translational biomarkers by F. Gastambide; J. Francois; M. Tricklebank; G. Gilmour (S200-S201).
P.1.g.020 Pretreatment with selective I2-imidazoline receptor ligands prevents kainic acid-induced neurotoxic signaling in the mouse hippocampus by B. Keller; J.A. García-Sevilla (S200).
P.1.g.022 Hallucinogenic and non-hallucinogenic 5-HT2A receptor agonists induce distinct patterns of G protein coupling in postmortem human brain by P. Miranda-Azpiazu; R. Díez-Alarcia; A. García-Bea; J. González-Maeso; B. Morentín; J.J. Meana (S201).
P.1.g.023 The antidepressant-like effect of P2 receptor blockade depends on serotonergic neurotransmission by M. Rodrigues; V.S. Pereira; P.C. Casarotto; S.R.L. Joca (S202).
P.1.g.024 Open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia by A. Maat; W. Cahn; H.J. Gijsman; J.E. Hovens; R.S. Kahn; A. Aleman (S202-S203).
P.1.g.019 Comparison of the effect of norquetiapine, reboxetine and citalopram on monoamine levels in rat locus coeruleus and prefrontal cortex by J.E. Ortega; I. Horrillo; E. Prieto; J.J. Me ana (S199-S200).
P.1.g.018 Serotonin receptor of type 6 (5-HT6) in human brain post-mortem. A pharmacology, immunohistochemistry and immunofluorescence study by S. Baroni; G. Giannaccini; L. Dell'Osso; D. Marazziti (S198-S199).
P.1.g.014 Vortioxetine, a novel multimodal antidepressant, modulates GABA and glutamate neurotransmission via serotonergic mechanisms by A. Pehrson; Y. Li; N. Haddjeri; M. Gulinello; C. Sanchez (S196-S197).
P.1.g.013 Effects of vortioxetine versus paroxetine on polysomnography in man: a pharmacokinetic/pharmacodynamic study by S. Wilson; J. Buchbjerg; A.M. Højer; J. Areberg; D.J. Nutt (S195-S196).
P.1.g.015 The role of valproic acid and levodopa on oxidative stress in a 6-hydroxydopamine lesioned rat model of Parkinson's disease by M. Dagdelen; H. Akkaya; E. Genc (S197).
P.1.g.016 Effects of tianeptine on mammalian target of rapamycin (mTOR) signaling in rat hippocampal neurons by M.K. Seo; C.H. Lee; H.Y. Cho; S.W. Park; B.J. Lee; J.G. Lee; Y.H. Kim (S197-S198).
P.1.g.017 BDNF-TrkB mediation of mechanical hyperalgesia in a rat model of chronic neuropathic pain by S. M'Dahoma; S. Barthélémy; B. Michot; F. Viguier; C. Tromilin; S. Pezet; M. Hamon; S. Bourgoin (S198).
S.28.03 Schizophrenia-related behavioural deficits caused by hippocampal and prefrontal disinhibition by T. Bast; S. McGarrity; R. Mason; K.C. Fone; M. Pezze (S153).
S.28.02 GABAergic interneurons and their role in neuronal synchronisation – implications for schizophrenia by H. Monyer (S152-S153).
S.07.08 Using Positron Emission Tomography to investigate microglial activation in alcohol dependence: preliminary findings by N.J. Kalk; Q. Guo; D.R. Owen; A. Waldman; K. Dar; R. Gunn; D.J. Nutt; E.A. Rabiner; A.R. Lingford-Hughes (S122).
S.07.07 Reward processing in unaffected siblings of schizophrenia patients: a functional magnetic resonance imaging study by M. De Leeuw; R.S. Kahn; M. Vink (S122).
S.08.01 Multi-scale modelling of neuronal networks – ion channel modulation leads to behavioural modifications by S. Grillner (S123).
S.08.02 Neural mechanisms of reinforcement learning: a computational approach by B.J. Richmond (S123).
S.08.04 Mathematical models of nicotine-induced neuroadaptations by B.S. Gutkin (S124).
S.08.03 Modelling extracellular neurotransmitter dynamics following chronic drug administration by H.R. Noori (S123-S124).
S.07.06 Epigenetic modifications of the BDNF gene at hippocampal level induced by chronic ethanol intake in C57BL/6J mice by E. Stragier; R. Massart; M. Hamon; L. Lanfumey (S121-S122).
S.07.05 Low performing rats model the inattentive subtype of adult ADHD in the 5-choice continuous performance task (5C-CPT) by A. Tomlinson; K.M. Marshall; J.C. Neill (S121).
S.07.01 A proteomic and functional analysis reveals that 5-HT6 receptors modulate neuronal differentiation by recruitment of Cdk5 by F. Duhr; M. Séveno; C. Marmoury la Cour; D. Dupuis; M.J. Millan; J. Bockaert; P. Marin; S. Chaumont-Dubel (S120).
S.06.04 Psychopharmacological treatments for adults with ADHD: new findings by E. Sobanski (S119).
S.07.02 Role of trace amine-associated receptor 1 (TAAR1) in the modulation of dopaminergic system and cortico-striatal signalling by S. Espinoza; I. Sukhanov; G. Lignani; L. Medrihan; S. Maggi; G. Giannotti; F. Fumagalli; F. Benfenati; V. Tucci; R.R. Gainetdinov (S120).
S.07.03 Endocannabinoid-mediated plasticity at inhibitory synapses on dopamine cells as a marker of vulnerability to addiction by C. Sagheddu; M. Melis; M. De Felice; G. Colombo; M. Pistis (S120-S121).
S.07.04 Effects of serotonin (5-HT)1B receptor ligands on amphetamine-seeking behaviour in rats by J. Miszkiel; E. Przegalinski (S121).
S.09.01 Anxiety, impulsivity and compulsivity in the development of stimulant dependence by K. Ersche (S124).
S.09.02 Altering the cortico striatal circuitry in impulsivity and compulsivity: new neuro-imaging findings by N.C. Vulink; D. Denys (S124-S125).
S.12.01 Identification of a significant role for the ventral hippocampus in neuropeptide S-elicited anxiolysis by I.A. Ionescu; J. Dine; J. Stepan; Y.C. Yen; L. Herrmann; F. Holsboer; C.T. Wotjak; R. Landgraf; M. Eder; U. Schmidt (S128-S129).
S.11.03 Epigenetic implications in schizophrenia, bipolar disorder and autism by H.M. Abdolmaleky (S128).
S.12.02 Histaminergic regulation of presumed serotonin neurons in the dorsal raphe nucleus by K. Panetta; J.J. Lambert; D. Belelli (S129).
S.12.03 Effect of early life experiences on brain structure and function: neurogenesis and decision making by M. Loi; S. Koricka; L. De Visser; M.J. Kas; P.J. Lucassen; M. Joels (S129).
S.12.04 Targeting postsynaptic density protein 95(PSD-95)/Discs large/Zonula occludens-1 (PDZ)-interactions of the glutamatergic synapse in animal models of depression by F. Freudenberg; V. Marx; V. Mack; L.E. Layer; M. Klugmann; P.H. Seeburg; R. Sprengel; T. Celikel (S129-S130).
S.11.02 Epigenetic control of stress-induced gene transcription and behaviour: relevance to PTSD by J.M.H.M. Reul (S127-S128).
S.11.01 Epigenetics in ageing and Alzheimer's disease by D. Van den Hove; L. Chouliaras; D. Mastroeni; P.D. Coleman; K.P. Lesch; H.W. Steinbusch; B.P. Rutten (S127).
S.09.04 Emotional regulation and impulsivity in borderline personality disorder: experimental and fMRI findings by G. Jacob; O. Tüscher (S125-S126).
S.09.03 The role of habit in obsessive-compulsive disorders: implications for pharmacotherapy by N.A. Fineberg; B.J. Sahakian; S.R. Chamberlain; C.M. Gillan; A.M. Apergis Schoute; S. Morein-Zamir; V. Voon; E. Bullmore; K. Jefferies; T.W. Robbins (S125).
S.10.02 Optimisation of treatment and management of schizophrenia in Europe: a multicenter European Study by R. Kahn; I.E. Sommer; I. Winter-van Rossum (S126).
S.10.03 Hyperprolactinemia in drug-naïve first-episode patients: data from EUFEST by A. Riecher-Rössler (S126).
S.10.04 Extrapyramidal and metabolic side effects of antipsychotic treatment: data from EUFEST by J.K. Rybakowski (S126-S127).
S.06.03 Persistence of brain deficits in adult ADHD by A. Cubillo; K. Rubia (S119).
S.06.02 Quantitative electroencephalographic assessment of ADHD by V. Simon (S118-S119).
S.01.03 Autism: from static genetic brain defect to dynamic gene-environment modulated pathophysiology by M.R. Herbert (S111-S112).
S.01.02 Matching preclinical and clinical studies: the translational challenge by J.C. Glennon; J.K. Buitelaar (S111).
S.01.04 Biomarkers and new target drugs in autism spectrum disorders by A.M. Persico; J.K. Buitelaar (S112).
S.02.01 Alterations in default mode network connectivity during pain processing in borderline personality disorder by R. Kluetsch; C. Schmahl; I. Niedtfeld; M. Densmore; V. Calhoun; J. Daniels; A. Kraus; P. Ludaescher; M. Bohus; R. Lanius (S112).
S.02.02 Dopamine D2 and serotonin 5-HT1A receptors of the brain in processing of pain by A. Pertovaara; I.K. Martikainen; N. Hagelberg; J. Hirvonen; H. Scheinin; J. Hietala (S113).
S.01.01 New neuroimaging approaches in autism spectrum disorders by C. Ecker (S111).
PL.06.01 Deafness: on the road from genes to therapy by K. Steel; C. Petit (S109).
PL.02.01 Novel therapeutic targets for neuroprotection and disease modification in Parkinson's disease by A. Björklund (S107).
Editorial Board (i).
PL.03.01 Understanding pain in somatoform disorders by C. Sommer (S107-S108).
PL.04.01 Autoimmune processes in encephalopathy: a promise for treatment of psychiatric disorders by A. Vincent (S108).
PL.05.01 The future of molecular pharmacology and drug discovery in psychiatry by M. Caron; N.M. Urs; S.M. Peterson; J.C. Snyder (S108-S109).
S.02.03 Placebo analgesia and beyond – the role of expectations in experiencing the world by P. Petrovic (S113).
S.02.04 Insular dysfunction and descending pain inhibition in anorexia nervosa by K.J. Bär; F. Beissner; G. Wagner (S113-S114).
S.05.02 New developments in the pharmacotherapy of bipolar disorders by J. Calabrese (S117).
S.05.01 Lithium: still a cornerstone in the long-term treatment of bipolar disorder? by W. Nolen (S116-S117).
S.05.03 Atypical antipsychotics in bipolar disorder and schizophrenia: similarities and discrepancies by S. Leucht (S117-S118).
S.05.04 The role of antidepressants in bipolar disorder by I. Pacchiarotti (S118).
S.06.01 Diagnostic criteria for ADHD in adults and changes under DSM 5 by P. Asherson (S118).
S.04.03 BDNF/TrkB signaling, axonal and dendritic transport and neurodegeneration in Huntington's disease by F. Saudou; D. Zala; P. Pla; M.V. Hinckelmann; G. Liot (S116).
S.04.02 Tau, axonal transport and Alzheimer's disease by E.M. Mandelkow; A. Sydow; K. Hochgräfe; Y. Kumar; H. Zempel; E. Mandelkow (S115-S116).
S.03.02 Disruption of thalamocortical activity by NMDA receptor antagonists: reversal by antipsychotic drugs by M. Hajos (S114).
S.03.01 Alterations of the hippocampal-prefrontal pathway in schizophrenia: effect of antipsychotic drugs by M. Spedding; E. Schenker; B.P. Godsil; T.M. Jay; C. Sebban; S. Takillah; P.H. Faure; C. Siok; M. Hajos; J. Bastlund; K. Wicke; F. Artigas (S114).
S.03.03 Dynamics of structural connections in schizophrenia by H.E. Hulshoff Pol (S114-S115).
S.03.04 Genetic alterations and functional brain changes in schizophrenia: fMRI studies by A. Meyer-Lindenberg (S115).
S.04.01 Long range transport of signals in axon injuries by M. Fainzilber (S115).
S.12.05 Serotonin regulates hippocampal synaptic plasticity and object memory in mice by S. Fernandez; A. Gruart; J.M. Delgado; P. Gaspar (S130).
S.12.06 Corticotropin releasing hormone and serotonin – the neuropsychopharmacology of fear learning deficit from rodents to humans by I. Heitland; L. Groenink; E.Y. Bijlsma; R.S. Oosting; J.M.P. Baas (S130).
S.23.04 Multimodal imaging of neuronal function and dysfunction by A. Drzezga (S145).
S.23.03 Imaging of the serotonin system by G.M. Knudsen (S145).
S.24.01 Rare mutations in N-methyl-D-aspartate glutamate receptors in schizophrenia and autism spectrum disorders by M.O. Krebs; O. Kebir; G. Rouleau (S146).
S.24.02 Effects of prenatal infection, a risk factor for schizophrenia, on hippocampal NMDA receptor function by P. Boksa; M.A. Burt; Y.C. Tse; T.P. Wong (S146).
S.24.03 Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors by M.W. Salter (S146-S147).
S.23.02 Imaging of the opioid and dopamine system by B. Rosen (S144-S145).
S.23.01 Current status of simultaneous MR-PET: an opportunity for neuropharmacological studies by T. Beyer (S144).
S.21.03 Psychiatric and behavioural side effects of anti-epileptic drugs by B. Schmitz (S143).
S.20.04 Application of mGlu5 receptor antagonists in L-DOPA induced dyskinesia and in fragile X syndrome by F. Gasparini (S142-S143).
S.22.02 Intervention directed at emotion recognition in delinquent adolescents by S.H.M. Van Goozen; K.L. Bowen; K. Main (S143).
S.22.03 Neuroimaging of fear conditioning and reward/punishment anticipation in the persistence of antisocial behaviour by M.D. Cohn; A. Popma; W. Van den Brink; L.E. Pape; M. Kindt; L. Van Domburgh; T.A.H. Doreleijers; D.J. Veltman (S143-S144).
S.22.04 Brain-regulation learning in criminal psychopaths by L. Konicar; R. Veit; U. Strehl; N. Birbaumer (S144).
S.24.04 Glycine reuptake inhibitor bitopertin: characterisation in relation to symptom domains in schizophrenia by D. Alberati (S147).
S.25.01 Pharmacogenetics of antidepressant, antiepileptic and neuroleptic drug treatment by L. Bertilsson; F.H. Hatta (S147).
S.27.02 Tauopathy and mitochondria by A. Eckert (S151).
S.27.01 Mitochondria and Aβ metabolism by M. Ankarcrona (S150-S151).
S.27.03 The role of AIF and PARP in mitochondria nucleus cross talk in AD by R. Strosznajder; K. Czubowicz (S151).
S.27.04 Therapeutic intervention at the mitochondrial level by W. Müller (S151-S152).
S.28.01 GABAergic interneuron synaptic dysfunction and schizophrenia by I. Del Pino; C. García-Frigola; E. Alvarez; M. Martínez de Lagran; G. Ciceri; M. Dierssen; S. Canals; O. Marín; B. Rico (S152).
S.26.04 Substance-specific effects of context on drug-induced neuronal activation in humans and animals by A. Badiani (S150).
S.26.03 Dopaminergic dysfunction and reward learning in bulimia nervosa by G. Hasler; P. Homan; S. Grob; U. Schnyder; G. Milos; H. Moeregeli (S150).
S.25.03 Pharmacogenetics of efficacy and treatment side effects in bipolar disorder by A. Serretti; C. Fabbri; A. Drago (S148).
S.25.02 Molecular genetic aspects to serotonergic drugs in bipolar disorder by X. Gonda (S148).
S.25.04 Genetics of suicidal behaviour in bipolar disorder: an update by A. Benabarre (S148-S149).
S.26.01 From dopamine to synaptic plasticity: the natural history of transition to addiction by J. Caboche; P. Vanhoutte; N. Heck (S149).
S.26.02 Genetic underpinnings of reinforcement in addictions by G. Schumann (S149).
S.20.02 Targeting glutamatergic transmission in the development of novel therapeutics for mood and anxiety disorders by G. Sanacora (S142).
S.20.01 The stress impact on glutamate transmission: a key to mood and anxiety disorders by M. Popoli; L. Musazzi; G. Treccani (S141-S142).
S.14.03 Relapse prevention with anxiolytic medication: results from a pharmacological MRI study by A. Gozzi (S134).
S.14.02 Testing the effect of alcohol intake and naltrexone treatment on brain networks using combined rsMRI/MEMRI in rats by S. Canals; A. Moreno; V. Pallarés; J. Pacheco-Torres; D. Moratal; F. De la Cruz; B. Fernández; R. Ciccocioppo; P. Hyytiä; W. Sommer (S134).
S.14.04 Testing the effect of modafinil on functional connectivity and impulsivity in alcohol dependent patients by L. Schmaal; A.E. Goudriaan; L. Joos; G. Dom; W. Van den Brink; D.J. Veltman (S134-S135).
S.15.01 Immunogenetics: a molecular approach to the modulation of emotion and cognitive processes by B. Baune (S135).
S.15.02 Childhood maltreatment and the course of depression: the role of inflammation by A. Danese (S135).
S.14.01 Can brain connectivity predict outcome in alcoholism treatment: the TRANSALC project by W.H. Sommer; W. Weber-Fahr; S. Vollstädt-Klein; M.W. Meinhardt; M. Brown; P. Hyytä; S. Canals; K. Mann; D. Hermann (S133-S134).
S.13.04 Nicotinic alpha7 treatments for improving cognitive symptoms – proof of concept and further developments by D. Hilt; M. Gawryl; N. Dgetluck; G. Koenig; H.J. Moebius; H. Meltzer (S133).
S.12.08 Lithium-regulated genes in peripheral cell models of bipolar-affective patients by S. Kittel-Schneider; M. Hilscher; S. Schreck; R. Schwarz; C.J. Scholz; L. Weißflog; A. Reif (S131).
S.12.07 Role of 5-HT1A/5-HT2A receptors interaction in the severity of depression and antidepressant response by G. Quesseveur; A.C. Petit; F. Gressier; R. Colle; D.J. David; A.M. Gardier; C. Verstuyft; C. Sanchez; E. Corruble; B.P. Guiard (S131).
S.13.011 Adherence to a single disease paradigm is not the way to move forward in the treatment of schizophrenia by C. Arango (S131-S132).
S.13.02 Novel mechanisms to improve negative symptoms – initial success and new directions by M. Berk; O. Dean (S132).
S.13.03 Guiding the development of new treatments for refractory schizophrenia – insights from PET and MRS studies of patients by O. Howes (S132-S133).
S.15.04 Role of Human Endogenous Retroviruses (HERVs) in psychotic disorder by H. Perron; R. Tamouza; M. Leboyer (S136).
S.16.01 Restoration of proliferation impairment of neural precursors in Down syndrome improves cognitive performances by E. Ciani; R. Bartesaghi (S136).
S.19.01 Impulsivity and compulsivity across mental disorders by T.W. Robbins (S140).
S.18.04 Influence of reproductive hormones on mood and anxiety in women: premenstrual dysphoric disorders by I. Sundström Poromaa; M. Gingnell; E. Bannbers; J. Wikström; J. Engman; M. Fredrikson (S139).
S.19.02 Dysfunction of reward anticipation in psychoses, affective disorders, addiction and ADHD – a transnosological correlate of negative mood by A. Heinz; C. Hägele; F. Schlagenhauf (S140).
S.19.03 The role of the subthalamic nucleus in motivational and reward processes by C. Baunez (S141).
S.19.04 Glutamatergic contributions to reward dysfunction in alcohol dependence by J. Krystal (S141).
S.18.03 Sex-hormone regulation and neuroimaging-markers of serotonergic neurotransmission and brain connectivity by V.G. Frokjaer; A. Pinborg; M. Heede; S. Henningson; C. Svarer; K.K. Holst; G.M. Knudsen (S139).
S.18.02 Sex hormonal fluctuations and the female human brain by J. Sacher; J. Hoyer; K. Arelin; K. Mueller; A. Villringer (S138).
S.17.01 Deep brain stimulation and apathy syndrome in Parkinson's disease: preclinical study by M. Savasta; S. Carnicella; S. Boulet (S137).
S.16.04 A non convulsant alpha5 selective GABA-A inverse agonist restores cognitive deficits in a mouse model of Down syndrome by B. Delatour; J. Braudeau; A. Duchon; L. Dauphinot; R.H. Dodd; Y. Hérault; M.C. Potier (S136-S137).
S.17.02 Modulating animal behaviour with deep brain stimulation – an approach for hypothesis development for deep brain stimulation by C. Winter; R. Hadar (S137).
S.17.03 The nucleus accumbens: a safe and well tolerated target for DBS in treatment resistant depression by B. Millet; F. Le Jeune; N. Jaafari; M. Polosan; B. Giordana; F. Naudet; J.M. Reymann; P. Fossati; P. Cornu (S137-S138).
S.17.04 New targets for deep brain stimulation in addiction by J. Luigjes; W. Van den Brink; D. Denys (S138).
P.1.g.054 Gene-expression imaging by N-methyl-D-aspartate receptor antagonists: implications for dopamine–glutamate interplay in psychosis by E.F. Buonaguro; F. Marmo; C. Sarappa; A. Eramo; C. Tomasetti; F. Iasevoli; A. De Bartolomeis (S220-S221).
P.1.g.055 5-HT2A/2C serotonergic receptors of lateral septal area modulate fear-induced responses elicited by activation of dorsolateral periaqueductal grey matter by R. De Oliveira; R.C. De Oliveira; N.C. Coimbra (S221-S222).
P.2.a.010 Serotonin transporter-siRNA rapidly exerts antidepressant effects following internalisation into serotonergic neurons by A. Ferres-Coy; F. Pilar-Cuellar; R. Vidal; M. Galofré; V. Paz; L. Campa; A. Montefeltro; E.M. Valdizan; F. Artigas; A. Bortolozzi (S313-S314).
P.2.a.009 Effects of chronic treatment with fluoxetine, moclobemide and agomelatine on rat isolated thoracic aorta by S.S. Gocmez; C. Ozer; D. Sahin; S. Karadenizli; T. Utkan (S313).
P.2.a.011 Chronic mild stress-induced behavioural and epigenetic changes in mice – prevention by agomelatine treatment by F. Boulle; R. Massart; L. Zaidan; S. Marday; C. Gabriel; E. Mocaër; M. Hamon; L. Lanfumey (S314-S315).
P.2.a.012 Electrophysiological effects of low doses of ketamine on the firing activity of norepinephrine and dopamine neurons by M. El Mansari; K. El Iskandarani; C. Oosterhof; P. Blier (S315).
P.2.a.014 The role of the GPR39-Zn2+-sensing receptor in the pathomechanism of depression by K. Mlyniec; U. Doboszewska; B. Budziszewska; G. Nowak (S316).
P.2.a.013 Antidepressant treatment and prefrontal cortex-hippocampus connection inhibition: communicating vessels? by V. Kafetzopoulos; N. Kokras; A. Vassalou; K. Antoniou; Z. Papadopoulou-Daifoti; C. Dalla (S315-S316).
P.2.a.008 Role of melatonin, 5-HT2B, and 5-HT2C receptors in modulating the firing activity of rat dopamine neurons by M. El Mansari; F. Chenu; P. Blier (S312-S313).
P.2.a.007 Early and time-dependent modulation of rat hippocampal miRNome during treatment with agomelatine by D. Tardito; M. Seguini; D. Corrada; I. Merelli; A. Mallei; L. Milanesi; G.A. Racagni; M. Popoli (S312).
P.2.a.003 Antidepressant-like effect of NOP receptor antagonist BAN ORL 24 by A. Twardowschy; R. Andreatini; N.C. Coimbra (S309-S310).
P.2.a.002 Stressful experience during peri-adolescent period induces depression-like phenotype in adult mouse by L. Lo Iacono; F. Visco Comandini; S. Puglisi-Allegra; V. Carola (S308-S309).
P.2.a.004 Study of the effect of personality in daily life experiences by E. Komulainen; K. Meskanen; P. Jylhä; J. Lahti; E. Isometsä; J. Ekelund (S310).
P.2.a.005 Antidepressant-like effect of 1,2,3,4-tetrahydroisoquinoline in forced swim test in comparison to citalopram by E. Mozdzen; J. Michaluk; A. Wasik; I. Romanska; L. Antkiewicz-Michaluk (S310-S311).
P.2.a.006 Effects of chronic diazepam and clomipramine treatment on mixed anxiety/depression conditions in male mice by A. Galyamina; I. Kovalenko; N. Kudryavtseva (S311).
P.2.a.015 MAPK pathway inhibition as target to potentiate the antidepressant-like effect of desipramine via the serotonergic system by S. Torres-Sanchez; J.A. Mico; E. Berrocoso (S317).
P.2.a.016 Electrode implantation produces an early response to deep brain stimulation in depression: potential role of regional neuroinflammation by L. Perez-Caballero; R. Perez-Egea; D. Puigdemont; C. Romero-Grimaldi; J. Molet; J.R. Caso; J.A. Mico; V. Pérez; J.C. Leza; E. Berrocoso (S317-S318).
P.2.b.008 Cognitive impairments in patients with depressive disorder and bipolar disorder by H.C. Kim; M.K. Kim; E.J. Lee (S323).
P.2.b.007 Efficacy and tolerability of bupropion in major depressive disorder associated with Parkinson's disease by D. Vasile; R.A. Macovei; O. Vasiliu (S322-S323).
P.2.b.009 Abnormality of white matter structure and resting state brain function in drug naive patients with major depressive disorder by M.L. Huang; L. Yu; N. Wei; J.B. Hu; B.Y. Lou; Y. Xu (S323-S324).
P.2.b.010 Genetic predictor of antidepressant response for major depressive disorder: a genome-wide association study and pathway analysis by W. Nakano; D. Mehta; M. Ising; H. Pfister; D. Czamara; F. Holsboer; S. Lucae; A. Erhardt-Lehmann; E.B. Binder (S324-S325).
P.2.b.011 Vortioxetine (Lu AA21004) 15 and 20 mg/day: open-label long-term safety and tolerability in major depressive disorder by G. Filippov; P.F. Christens (S325).
P.2.b.006 Depression and apathy in patients with Parkinson's disease in a hospital in Romania by M.M. Dumitru; R. Chirita; V. Chirita (S322).
P.2.b.005 Psychopharmacological treatment of patients with schizoaffective disorder in comparison to schizophrenia and bipolar disorder by H.J. Assion; A. Schweppe; M. Skiba; G. Juckel (S321-S322).
P.2.b.001 Cognitive functioning after deep brain stimulation in subcallosal cingulate gyrus for treatment-resistant depression by M. Serra-Blasco; S. De Vita; M. Rivas; J. De Diego; D. Puigdemont; A. Martin-Blanco; E. Alvarez; V. Pérez; M.J. Portella (S318-S319).
P.2.a.017 Effects of hypergravity on serotonin-related gene expression in the mouse brain by M. Yoshioka; S. Inubushi; T. Ochiai; M. Miyamoto; Y. Ohira; H. Ohta (S318).
P.2.b.002 Comparative analysis of agomelatine and trazodone in late-onset major depression by D. Vasile; O. Vasiliu; C. Tudor; A.G. Mangalagiu; O. Magazin; G.A. Sopterean; R.E. Bratu (S319-S320).
P.2.b.003 Mirtazapine versus sertraline in the treatment of post-psychotic depression by D. Vasile; O. Vasiliu; A.G. Mangalagiu; G.A. Sopterean; R.E. Bratu (S320).
P.2.b.004 Improvement in subjective and objective neurocognitive functions in patients with major depressive disorder: tianeptine versus escitalopram by H.J. Jeon; J.M. Woo; S.H. Lee; E.J. Kim; S.H. Chung; J.H. Ha; M. Fava; D. Mischoulon; J.H. Kim; B.H. Yu (S320-S321).
P.2.a.001 Social interaction with a rhythmic rat prevents depressive-like behaviour induced by constant light by B.J. Martynhak; L.K.S. Kanazawa; G.M. Nascimento; R. Andreatini (S308).
P.1.k.015 Bayesian tools for optimizing adaptive clinical trials by C. Siu; C. Brambilla; F. Ruggeri (S307-S308).
P.1.j.026 Cognitive deficits caused by hippocampal disinhibition: attentional and memory deficits by S. McGarrity; K.C. Kevin; R. Mason; M.A. Pezze; T. Bast (S296-S297).
P.1.j.025 Abnormal cognitive salience but not WCST scores are associated with poor outcome in patients with schizophrenia by H. Bergaoui; A. Frajerman; M. De Hert; C. Tessier; P. Nuss (S296).
P.1.j.027 Insight into illness and subjective quality-of-life assessment in chronic schizophrenia by C. Siu; O. Agid; M. Waye; C. Brambilla; G. Remington; P. Harvey (S297).
P.1.j.028 Dissecting reward processing in the brain: a human experimental model for biomarker discovery in major depressive disorder by C. McCabe (S297-S298).
P.1.j.029 Implications of paranoid ideation on the social cognition of the depressive-delusional spectrum by C. Giurgi-Oncu; C. Bredicean (S298).
P.1.j.024 Theory of mind deficit in bipolar patients with subsyndromal illness by M. Simon; R. Herold; A.S. Hajnal; E. Varga; S. Fekete; T. Tényi (S295-S296).
P.1.j.023 Social cognition and executive deficits in bipolar disorder and schizophrenia: preliminary data by M. Cigliobianco; E. Caletti; P. Grillo; A. Caldiroli; M. Serati; G. Orsenigo; E. Zugno; R.A. Paoli; S. Zago; A.C. Altamura (S295).
P.1.j.019 Cognitive deficit in myotonic dystrophy type 1 by Y.G. Park; S.M. Kim; Y.C. Choi (S292-S293).
P.1.j.018 Deletion of cannabinoid-2 receptors induces memory impairment associated with synaptic plasticity alterations by M. García-Gutiérrez; A. Ortega-Alvaro; A. Busquets; J.M. Péirez-Ortiz; L. Caltana; M.J. Ricatti; A. Brusco; R. Maldonado; J. Manzanares (S291-S292).
P.1.j.020 Specific white-matter connectivity alterations in posttraumatic-stress disorder patients: correlation to associative memory deficits by R. Saar-Ashkenazy; J. Cohen; J. Guez; C. Gasho; I. Shelef; A. Friedman; H. Shalev (S293).
P.1.j.021 Cognitive abilities are changed in gamma-synuclein knockout mice by V. Kokhan; G. Van'kin; I. Shamakina (S293-S294).
P.1.j.022 A dopamine D1 agonist improved ketamineinduced spatial working memory dysfunction in common marmosets by T. Nakako; T. Murai; M. Ikejiri; T. Ishiyama; M. Taiji; K. Ikeda (S294).
P.1.k.001 Psychiatric disorders, violence and their relationship with substance abuse by J. León Caballero; M. Llobet Farré; D. Córcoles Martínez; M. Bellsola González; A. González Fresnero; M.T. Nascimento Osorio; M.A. Malagon Amor (S299).
P.1.k.002 Epidemiological 3-year follow-up study on vascular depression in an elderly Korean population by J.H. Park; T.H. Kim; B.I. Yoo; J.W. Han; K.W. Kim (S299-S300).
P.1.k.011 Parenting in early childhood: structural and criterion validity of the Parenting Attitudes towards Infants and Toddlers questionnaire by J. Wittich; A. Strobel; H.U. Wittchen; J. Martini (S305).
P.1.k.010 Depression and anxiety in patients with Crohn's disease by L. Trikos; A. Jovanovic; D. Bojic; N.J. Jojic (S304).
P.1.k.012 Detecting domestic violence: the use of revised Conflict Tactics Scale (CTS-2) in Italy by E. Arcidiacono; M.S. Signorelli; E. Aguglia (S305-S306).
P.1.k.013 Mental health of single fathers and single mothers in single parent families living in an urban community in South Korea by S.I. Kim; E.J. Kim (S306-S307).
P.1.k.014 Attenders of a Portuguese university hospital's psychiatric emergency service: general characteristics and gender differences by S. Pereira; P. Garrido; H. Bastos; F. Polido; A. Craveiro (S307).
P.1.k.009 Care programme approach: is there a difference in treatment perceived by service users by N. Chakraborty; S. Ahmed (S303-S304).
P.1.k.008 Is Type A behavior pattern protective of diabetes complication? A study in 400 patients with diabetes by J. Chauvet-Gelinier; B. Verges; B. Trojak; E. Ponavoy; B. Bouillet; V. Meille; M. Benetti; M. Briki; I. Robin; B. Bonin (S303).
P.1.k.004 Sociodemographic and clinical characteristics of involuntary admissions in patients with schizophrenia and bipolar disorder by S.L. Romero Guillena; B.O. Plasencia Garcia de Diego; N. Casas Barquero; L. Muñoz García-Largo (S300-S301).
P.1.k.003 Somatisation and alexithymia in general medical practice by I. Natsov; G. Hranov; L.G. Hranov (S300).
P.1.k.005 Co-morbidity between epilepsy and severe psychiatric illness: a population-based study by O. Kapara; E. Feruchter; A. Reichenberg; R. Yoffe; O. Fono-Yetiv; I. Kreiss; M. Davidson; M. Weiser (S301-S302).
P.1.k.006 Impulse control disorders in elderly patients by L. Tamam; M. Bican; N. Keskin (S302).
P.1.k.007 Prevalence and related risk factors of suicidal ideation of adolescents in an urban area by S.J. Cho; T.H. Lee; Y.J. Lee; S.J. Kim; K.S. Oh (S302-S303).
P.2.b.012 Vilazodone improves anxiety symptoms in patients with major depressive disorder: a pooled analysis of efficacy by J. Edwards; D. Chen; A. Ruth; M.E. Thase (S325-S326).
P.2.b.013 Early improvement and sustained response with vilazodone in patients with major depressive disorder – pooled analyses from phase III trials by R. Jain; D. Chen; J. Edwards; M. Mathews (S326).
P.2.b.050 Mineralocorticoid receptor function a predictor of treatment response in depression with or without early life stress by M.F. Juruena; A.C. Moreira; M. Castro; F.G. Graeff (S348-S349).
P.2.b.049 Increasing signal over noise in MDD clinical trials: improvement after efficacy scale rater training among experienced MDD investigators by J. Busner; A. Kott; G. Sachs (S348).
P.2.b.051 Cognitive impairment and decreased quality of life in elderly patients with subsyndromal depression by C.I. Lee; J.S. Ryu; M.D. Kim; J.H. Park (S349-S350).
P.2.b.052 Assessing the stress perceived by caregivers of patients with major depressive episode: major depressive disorder versus bipolar disorder by L. Oldani; B. Dell'Osso; C. Arici; C. Dobrea; M. Serati; A.C. Altamura (S350).
P.2.b.054 Psychiatric induced disorders and quality of life of substance abusers with chronic hepatitis C under interferon-alpha treatment by J. Moreno; M. Udina; R. Navines; P. Castellvi; M. Torrens; R. Sola; R. Martín-Santos (S351).
P.2.b.053 Treatment adherence in recurrent depression and self-esteem: a correlation study by M. Radu; L. Paziuc; R. Chirita (S350-S351).
P.2.b.048 Functional impairment in major depressive disorder: preliminary findings of the PERFORM study by D. Saragoussi; J.M. Haro; J.P. Boulenger; F.X. Lamy; S. Di Nicola; B. Rive (S347-S348).
P.2.b.047 Leptin and depressive symptoms in anorexia nervosa – longitudinal study by F. Rybakowski; M. Tyszkiewicz-Nwafor (S347).
P.2.b.043 Glucocorticoid receptors, serotonin and dopamine neurotransmission are associated with interferon-induced depression by M. Udina; R. Navinés; I. Grande; A.E. Nardi; K. Langohr; M. Gratacòs; E. Vieta; M. Valdés; R. Solà; R. Martín-Santos (S344-S345).
P.2.b.042 Escitalopram effectiveness in depressed patients suffering from neurological disorders – data from an open label study in Greece by P. Sakka; E. Papalexi; E. Chourdaki; C. Skamnelos; I.A. Parashos (S343-S344).
P.2.b.044 Serotonin transporter association between dorsal raphe and ventral striatum is diminished in major depression by A. Hahn; D. Haeusler; C. Kraus; A.S. Höflich; G.S. Kranz; P. Baldinger; M. Mitterhauser; W. Wadsak; S. Kasper; R. Lanzenberger (S345).
P.2.b.045 Treatment of major depression reduces arterial stiffness by N. Kokras; A.V. Kouzoupis; C. Papamichael; G.N. Papadimitriou; K.S. Stamatelopoulos (S345-S346).
P.2.b.046 Effects of metabolic syndrome on the treatment response of in-patients with major depressive disorder by H. Jung; S. Lee; S. Kim; K. Na; B. Lee (S346-S347).
P.2.b.055 Suicide intent is associated with temporally proximal insomnia and short sleep duration independently of current major depression by P. Ferentinos; C. Christodoulou; E. Porichi; L. Lykouras; I. Liappas (S351-S352).
P.2.b.056 Time course of psychomotor performances, fatigue and cognitive function in stable in-patients with treatment resistant depression by D. Neu; O. Mairesse; S. Ammendola; J. Newell; C. Kornreich; P. Verbanck (S352).
P.2.c.005 Myricitrin, a PKC inhibitor, exerts antimanic-like effects in animal models by R. Andreatini; M. Pereira; I.P. Siba; M.G. Pizzolatti; A.R.S. Santos; A.P. Ruani (S357-S358).
P.2.c.004 Frontopolar inefficiency and anterior cingulate overactivation during working memory: early stage abnormalities in bipolar disorder by J.M. Goikolea; D. Dima; I. Torres; R. Landín-Romero; G. Delvecchio; M. Valentí; B. Amman; E. Pomarol-Clotet; E. Vieta; S. Frangou (S357).
P.2.c.006 The role of tetraspanin 8 in bipolar disorder by C. Schartner; C.J. Scholz; H. Weber; L. Weißflog; A. Reif (S358-S359).
P.2.c.007 Volumetric brain MRI study of the correlation between brain area and cognitive function in elderly bipolar patients by J. Lee (S359).
P.2.c.008 Increased mitochondrial lipid peroxidation in depression bipolar episode by L. Jornada; A. Steckert; F. Scussel; G. Ferreira; E. Streck; P. Ferrari; B. Pfaffenseller; M. Costanzi; L. Czepielewski; J. Quevedo (S359-S360).
P.2.c.003 Subjective Well-being under Neuroleptic Scale in outpatients with bipolar disorder by S.L. Romero Guillena; F. Gotor; O. Santamaria (S356-S357).
P.2.c.002 The visuospatial and executive dysfunction in adult patients with bipolar I disorder type by G.N. Verbenko (S356).
P.2.b.058 The relevance of oxidative stress status in first episode and recurrent depression by M. Padurariu; A. Ciobica; C. Stefanescu (S353-S354).
P.2.b.057 Prevalence of depression in elderly patients with chronic physical illness by H. Lee; S. Hahn; S. Shim; Y. Kwon; H. Jeong (S353).
P.2.b.059 A common neurobiology for reward, chronic pain and depression? A [11C]raclopride bolus plus constant infusion PET-study by K. Ledermann; J. Jenewein; H. Sprott; G. Hasler; U. Schnyder; C. Burger; A. Johayem; S. Kollias; A. Buck; C. Martin-Soelch (S354).
P.2.b.060 Language phenomenon in the diagnostic criteria of mild depression by D. Smirnova; E. Sloeva; N. Kuvshinova; A. Krasnov; M. Ustinov; D. Romanov; G. Nosachev (S354-S355).
P.2.c.001 Mood disorder and obesity: policy and evidence revisited by A.E. Schmidt; E.Z. Reininghaus (S355-S356).
P.2.b.041 Depression, antidepressants and alcohol use affects suicidal ideation in primary care patients by V. Liaugaudaite; J. Peceliuniene; N. Raskauskiene; N. Mickuviene; R. Bunevicius (S343).
P.2.b.040 Inflame-Beat: insufficient glucocorticoid signalling and inflammatory activation in coronary heart disease patients with depression by L.A. Carvalho; N. Nikkheslat; C.M. Pariante (S342-S343).
P.2.b.022 Worsening conditions for the depressive mental states with aging in Japanese patients with subacute myelo-optico-neuropathy (SMON) by T. Konishi; K. Hayashi; M. Fujita (S331-S332).
P.2.b.021 Clinical course of disease and epileptic seizures in patients with bipolar disorder and a history of traumatic brain injury by O.K. Drange; A.E. Vaaler; G. Morken; P.I. Finseth (S331).
P.2.b.023 Psychosocial factors and their relationships with suicidal ideation in middle-aged unemployed people by D. Jon; A. Hong; A. Kwon; M. Jung; H. Hong (S332).
P.2.b.024 Efficacy of antidepressants in the treatment of major depressive disorder: a naturalistic study by A. Balagué Anó; M.V. Ollés; P. Gento; E. Turnes; J. Calvo (S332-S333).
P.2.b.025 Decrease of homocysteine levels after pharmacological treatment in patients with unipolar and bipolar depression by A. Permoda-Osip; J. Dorszewska; M. Chlopocka-Wozniak; J.K. Rybakowski (S333).
P.2.b.020 Safety and tolerability of levomilnacipran SR in major depressive disorder: results from an open-label, 48-week extension study by R. Mago; G. Forero; W.M. Greenberg; C. Gommoll; C. Chen (S330).
P.2.b.019 Clock gene polymorphisms and haplotypes in mood disorder in a Polish cohort by M. Wilkosc; M. Wegalrz; M. Maciukiewicz; J. Pawlak; A. Leszczynska-Rodziewicz; J. Hauser (S329-S330).
P.2.b.015 iNOS gene expression correlates with cognitive impairment in recurrent depressive disorder by M. Talarowska; P. Galecki (S327-S328).
P.2.b.014 Results of the German non-interventional study VITAL over 6 months: effect of agomelatine on depressive symptoms and patients' compliance by M. Lemke; B. Barthel (S327).
P.2.b.016 Effectiveness of duloxetine monotherapy compared to combination therapy with other antidepressants in patients with depression by J.Y. Lee; J.K. Sakong; J.B. Lee; E.J. Cheon; B.H. Koo; D.S. Bai; S.H. Song (S328).
P.2.b.017 Distribution pattern of activity shifts in accordance with improvement of depressive symptoms in patients with depressive episode by J. Noh; S. Yoo; E. Lee; Y. Kwon; N. An; J. Lee; J. Park; Y.K. Chung (S328-S329).
P.2.b.018 Post hoc analyses of levomilnacipran SR 40, 80, and 120 mg on functional outcomes in major depressive disorder by C. Gommoll; W.M. Greenberg; C. Chen; L. Citrome (S329).
P.2.b.026 Social adjustment among therapy responder patients with mood disorders by A. Chiesa; A. Serretti; D. Souery; R. Calati; O. Sentissi; S. Kasper; E. Akimova; J. Zohar; D. Amital; S. Montgomery (S334).
P.2.b.027 A phase II randomized, double-blind, placebo-controlled trial of GLYX-13 for the rapid treatment of major depressive disorder (MDD) using central ratings by D. Popp; R. Burch; J.B.W. Williams; L.M. Price; M.J. Detke (S334-S335).
P.2.b.036 BDNF: an indicator of insomnia? by M. Giese; E. Unternährer; H. Hüttig; J. Beck; S. Brand; P. Calabrese; E. Holsboer-Trachsler; A. Eckert (S340).
P.2.b.035 Metabolic syndrome and C-reactive protein in patients with depressive disorder on antidepressive medication by I. Popovic; D. Ravanic; A. Stanojevic; V. Popovic; S. Vladejic (S339-S340).
P.2.b.037 Mirtazapine augmentation following response failure with SSRI monotherapy in subjects with major depressive disorder by A. Dzubur Kulenovic; A. Kucukalic; A. Bravo-Mehmedbasic (S341).
P.2.b.038 How to switch to agomelatine after an initial treatment failure of paroxetine or venlafaxine? by M. Lejoyeux; F. Picarel-Blanchot; C. De Bodinat (S341-S342).
P.2.b.039 An observational study to evaluate social and occupational functioning in depressed patients treated with escitalopram by D. Podea; R. Georgescu (S342).
P.2.b.034 Somatic symptoms and late life depression: focus on the association of the number of somatic symptoms with severity of depression by I.K. Jung; S.J. Kim (S339).
P.2.b.033 A randomized study of escitalopram and paroxetine controlled-release in the treatment of Japanese patients with major depressive disorder by T. Kishi; K. Kawashima; M. Moriwaki; Y. Otake; T. Mukai; Y. Matsuda; K. Fujita; N. Iwata (S338).
P.2.b.029 Levomilnacipran SR efficacy in major depressive disorder (MDD) across patient subgroups: pooled analysis of 5 double-blind, placebo-controlled trials by S. Montgomery; C. Gommoll; C. Chen; W.M. Greenberg (S336).
P.2.b.028 12-month and point prevalence of depression and related characteristics in Latvian population assessed by the Mini International Neuropsychiatric Interview (MINI) in 2012 by J. Vrublevska; E. Rancans; M. Trapencieris; S. Snikere (S335).
P.2.b.030 Levomilnacipran SR and functional efficacy in major depressive disorder: pooled analyses of 5 double-blind, placebo-controlled trials by A. Sambunaris; C. Gommoll; C. Chen; W.M. Greenberg (S336-S337).
P.2.b.031 Differences in memory function between 5-HT1A genotypes in patients with major depressive disorder by K. Wesnes; S.C. Hopkins; K.S. Koblan (S337).
P.2.b.032 Neural correlates of emotion regulation response to negative stimuli in young women at high risk for depression by F. Simsek; O. Kaya; S. Akan; D. Haznedaroglu Isman; D. Acikel; O.M.E.R. Kitis; S. Cetinkalp; M. Eker; K. Coburn; A. Gonul (S337-S338).
P.1.j.017 Protective effects of resveratrol in aging-induced cognitive impairment in rats by S. Gocmez; N. Gacar; T. Utkan (S291).
P.1.j.016 Adulthood isolation stress enhances both long- and short-term potentiation in rats by B. Tan; F. Deneme; S. Bitiktas; S. Kavraal; M. Ascioglu; C. Suer (S290-S291).
P.1.h.003 Orexin A receptor antagonist SB-408124 attenuates the effect of amphetamine on the brain reward system by A.A. Lebedev; E.R. Bychkov; P.P. Khokhlov; E.G. Shumilov; R.O. Roik; P.D. Shabanov (S244).
P.1.h.002 Chronic effects of a benzodiazepine site inverse agonist on rat behavior in the forced swim test: a comparison with fluoxetine by J. Samardzic; D.I. Obradovic (S243-S244).
P.1.h.004 Monoaminergic systems mature in rat offspring brain in pre- and early postnatal period after maternal alcoholisation by P.D. Shabanov; E.R. Bychkov; M.I. Airapetov; E.A. Sekste; R.O. Roik; A.A. Lebedev (S245).
P.1.h.005 Extended effects of chronic social stress on the behaviors of adolescents in adulthood by I.L. Kovalenko; D.A. Smagin; A.G. Galyamina; N.N. Kudryavtseva; G.N. Enikolopov (S245-S246).
P.1.h.007 Blockade of 5-HT1A receptor corrects anxiety-like behaviour in gonadectomized male rats of middle age treated with low dose of testosterone by J. Fedotova (S246-S247).
P.1.h.006 Anti-allodynic effects of agomelatine combined with gabapentin in neuropathic rats with infraorbital nerve constriction by S. Bourgoin; B. Michot; N. Deraredj; M. Bertrand de Laujardière; C. Gabriel; E. Mocaër; M. Hamon (S246).
P.1.h.001 Antidepressant-like effects of myricitrin, an inhibitor of nitric oxide and PKC, in animal models by M. Pereira; I.P. Siba; M.G. Pizzolatti; R. Andreatini (S243).
P.1.g.089 Demographic evaluation of patients treated with transcranial direct current stimulation (TDCS) in a university hospital by G. Eryilmaz; B. Onen Unsalver; G. Gogcegoz; E. Saglam (S242-S243).
P.1.g.085 Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia – a 1-year non-interventional study by A. Schreiner; A. Svensson; R. Wapenaar; P. Cherubin; P. Princet; L. Serazetdinova; N. Starostina; M. Zink (S240).
P.1.g.084 Prevention of nicotine-induced kindling in female periadolescent rats by the repeated administration of N-acetylcysteine by C. Custodio; B.S.F. Mello; A.M.N. Costa; P.X.L. Gomes; G.V. Oliveira; F.Y.R. Araujo; F.C.F. Sousa; A.F. Carvalho; D.S. Macedo (S239-S240).
P.1.g.086 The formation of serotonin from 5-methoxytryptamine via cytochrome P450 in the brain in vivo – a microdialysis study by E. Bromek; A. Haduch; K. Golembiowska; W.A. Daniel (S240-S241).
P.1.g.087 Hyperammonemic encephalopathy caused by combined electroconvulsive therapy and valproate use by G. Eryilmaz; C. Salcini; B. Onen Unsalver; I. Gogcegoz; E. Saglam (S241).
P.1.g.088 Cyclo-L-prolylglycine reduced haloperidol-induced catalepsy in BALB/c mice by M.N. Vukolova; T.A. Gudasheva (S242).
P.1.h.008 Psychosocial stress counteracts behavioural changes associated with experimental colitis by P. Jain; A.M. Hassan; P. Holzer (S247).
P.1.h.009 A2a adenosine receptors as therapeutic targets in schizophrenia: behavioural characterisation of A2a knockout mice by M. Moscoso-Castro; I. Gracia-Rubio; J. Ruiz-Medina; O. Valverde (S247-S248).
P.1.h.018 Acute methamphetamine exposure induces long-lasting depressive-like behavior in mice by C. Fontes Ribeiro; C. Silva; A.F. Neves; H.J. Freitas; A.I. Dias; S.M. Mendes; I. Pita; S.D. Viana; R. Prediger; F. Pereira (S253).
P.1.h.017 Regulation of the level of LSAMP gene and protein by alternative promoters in mouse brain and implications in behavioral models by M. Philips; K. Lilleväli; J. Innos; H. Luuk; C.A. Hundahl; I. Heinla; E. Vasar (S252-S253).
P.1.h.019 Different patterns of c-fos expression in conditioned place aversion induced by haloperidol or by social transfer in mice by D.F. Fukushiro; T.C.F. Aramini; R.A. Uehara; R. Frussa-Filho (S253-S254).
P.1.h.020 Effect of basolateral amygdala lesions on anxiety and spatial memory in a rat model of autism by K. Ptaszek; K. Plucinska; D. Myslinska (S254).
P.1.h.021 Sequential structure of agonistic behaviour is modified after paramethoxyamphetamine (PMA) administration in male mice by A.T. Muela; M. Martín-López; M. Cavas; J.F. Navarro (S254-S255).
P.1.h.016 Robust and reproducible detection of distributed resting-state networks in the mouse brain by F. Sforazzini; A.J. Schwarz; A. Galbusera; A. Bifone; A. Gozzi (S252).
P.1.h.015 Differential effect of c-Fos activation associated with JNJ16259685 after an agonistic encounter as compared with grouped mice by V. De Castro; D. Suárez-Boomgaard; A. Rivera; M. Martín-López; J.F. Navarro (S251).
P.1.h.011 Studies on the effects of some Bidens tripartita extracts on psychomotor abilities in rats by R.B. Sandu; C.E. Lupusoru; R.V. Lupusoru; L. Tartau (S248-S249).
P.1.h.010 Early life influences on emotional reactivity, social behaviour and neuroinflammation by I. Gracia-Rubio; M. Moscoso-Castro; J. Ruiz-Medina; O. Valverde (S248).
P.1.h.012 Changes in alpha(1D)-adrenergic receptor expression and working memory of female mice with selective glucocorticoid receptor ablation by P. Chmielarz; G. Kreiner; A. Zelek-Molik; I. Nalepa (S249-S250).
P.1.h.013 Agomelatine induces antihyperalgesic effects in a rat model of neuropathic pain and produces an additive interaction with gabapentin by C. Chenaf; E. Chapuy; C. Courteix; F. Libert; M. Bertrandde Laujardière; C. Gabriel; E. Mocaër; A. Eschalier (S250).
P.1.h.014 The effects of mitochondrial mediators on spontaneous activity and balance by T. Alexa; A. Dondas; A. Luca; A. Negru; I. Stanciuc; C.E. Gherca; A. Mihai; C.R. Bohotin (S250-S251).
P.1.g.083 Determination of the alterations in prepulse inhibition in mice treated with doxycycline in an animal model of depression by B.S.F. Mello; C.S. Custodio; B.M.M. Ribeiro; R.C. Cordeiro; J.V. Santos; P.X.L. Gomes; F.C.F. Sousa; H.V. Nobre; A.F. Carvalho; D.S. Macedo (S238-S239).
P.1.g.082 Cognitive enhancement drugs in experimental chronic hyperglycemia – role of platelets and endothelium by A.E. Lievykh; V.I. Zhylyuk; V.I. Mamchur (S238).
P.1.g.064 Comparison of sensorimotor gating and quantitative EEG in serotonergic models of psychosis in the rat by F. Tyls; T. Palenicek; M. Fujakova; L. Kaderabek; P. Novakova; A. Kubesova; J. Horacek (S227).
P.1.g.063 Inhibition of neuronal nitric oxide synthase in the prelimbic cortex prevents the panic-like reaction organised by medial hypothalamus by R.L. De Freitas; J.E.C. Hallak; J.A.S. Crippa; N.C. Coimbra (S226-S227).
P.1.g.065 Involvement of M2 muscarinic receptors of locus coeruleus in post-ictal antinociception by T. Paschoalin Maurin; R.C. De Oliveira; N.C. Coimbra (S227-S228).
P.1.g.066 The genetic deletion of the Lsamp gene in mice induces age-dependent changes in the phenotype by J. Innos; I. Aug; A. Bregin; T. Mazitov; M.A. Philips; E. Vasar (S228).
P.1.g.067 Tianeptine has neuroprotective effects in a differentiated SH-SY5Y human neuroblastoma cell line by G. Colpo; G.R. Fries; P. Ferrari; F. Klamt; F. Kapczinski (S229).
P.1.g.062 Reduction in serotonin 5-HT2C receptor antagonist-induced effects on theta power after chronic escitalopram treatment in rats by D. Kostyalik; Z. Kátai; S.Z. Vas; D. Pap; B. Horváth; I. Gyertyán; L. Tóthfalusi; G.Y. Bagdy (S225-S226).
P.1.g.061 5-HT6 receptor antagonist-induced alterations in SAPK/JNK signalling in a rat neurodevelopmental model of schizophrenia by M.V. King; O.H. Negm; P.J. Tighe; K.C.F. Fone (S225).
P.1.g.057 Relationship between plasma and tissue ghrelin levels and antimuscarinic induced convulsions in fasted mice after food intake by A. Zengin Turkmen; A. Nurten (S222-S223).
P.1.g.056 A multireceptor ligand ACz37 representing a new series of arylpiperazine analogs with antipsychotic and antidepressant activity in mice by A. Wesolowska; A. Czopek; A. Partyka; A. Wasik; D. Wrobel; M. Jastrzebska-Wiesek; A. Zagorska; M. Kolaczkowski; M. Pawlowski (S222).
P.1.g.058 The influence of brain serotonergic system on the expression and activity of cytochrome P450 in the liver by M. Rysz; E. Bromek; A. Haduch; W.A. Daniel (S223).
P.1.g.059 Effects of antiepileptic drugs on the physical working capacity of rats by M. Shishmanova; K. Georgieva; L. Peychev (S223-S224).
P.1.g.060 The effect of mesenchymal stem cells on allodynia, electrophysiologic and histologic parameters in an experimental neuropathy model by F. Aksu; O. Ergürhan Kiroglu; A. Alizadeh Yegani; E. Maytalman; M. Emre; S. Zorludemir; S. Mete (S224-S225).
P.1.g.068 CB1 endocannabinoid receptors of inferior colliculus modulate the catalepsy induced by haloperidol in rodents by P. De Medeiros; R. De Freitas; N.C. Coimbra; L. Melo-Thomas (S229-S230).
P.1.g.069 Aberrant ligand–receptor dynamics of the muscarine-M1 agonist AF150(S) by J.E. Leysen; E.W.E. Verweij; M. Verlaan; K. De Waepenaert; I. Fonteyn; C.F.M. Molthoff; A. Fisher; A.D. Windhorst; H.J.C. Buiter; A.A. Lammertsma (S230).
P.1.g.078 Approaches to create dietary supplements to prevent postpartum depression by Y. Dowlati; A. Ravindran; Z. Segal; M. Steiner; J.H. Meyer (S235-S236).
P.1.g.077 Effects of clozapine on the prepulse inhibition of rats submitted to the model of schizophrenia induced by neonatal immune challenge by B.M.M. Ribeiro; C.S. Custodio; B.S.F. Mello; R.C. Cordeiro; J.V. Santos; A.T. Menezes; M.L. Vale; S.M.M. Vasconcelos; A.F. Carvalho; D.S. Macedo (S235).
P.1.g.079 Dopaminergic neurotransmission in clinical and genetic high risk populations for psychosis by T. Van Amelsvoort; O. Bloemen; E. Boot; M. De Koning; J. Booij (S236).
P.1.g.080 Modulation of cognitive function and 5-HT hippocampal levels in socially isolated rodents after peptidomimetic treatment by E. Encheva; L. Tancheva; L. Alova; V.V. Petkov; R. Klissurov; M. Novoselski; D. Tsekova; N. Belova (S237).
P.1.g.081 Zinc depletion impairs behaviour and alters trace elements profile in serum and brain structures by U. Doboszewska; B. Ostachowicz; B. Szewczyk; G. Nowak (S237-S238).
P.1.g.076 Determination of the immunoexpression of iNOS in the hippocampus of rats submitted to the Poly I:C-induced model of schizophrenia by B.M.M. Ribeiro; B.S.F. Mello; C.S. Custodio; P.X.L. Gomes; M.R.S. Carmo; M.L. Vale; A.T. Menezes; D.F. Lucena; S.M.M. Vasconcelos; D.S. Macedo (S234-S235).
P.1.g.075 Gender differences in routes of drug administration in involuntarily admitted patients – changes from 1997 to 2007 by A. Rauch; M. Edlinger; T. Wolfinger; G. Kemmler; N. Yalcin-Siedentopf; W.W. Fleischhacker; A. Hofer (S234).
P.1.g.071 Possible benefits of a combination of physical activity and levodopa administration in a rat model of Parkinson-like disease by C.S. Custodio; J.V. Santos; A.C.V. Gomes; R.C. Cordeiro; A.S. Monte; B.S.F. Mello; B.M.M. Ribeiro; L.D. Belchior; D.S. Macedo (S231-S232).
P.1.g.070 Dopaminergic and serotonergic dysfunctions induced by methamphetamine in mice are decreased by aerobic exercise by C.A. Fontes Ribeiro; A.F. Neves; H.J. Freitas; A.I. Dias; S.M. Mendes; S.D. Viana; S. Nunes; F.C. Pereira (S231).
P.1.g.072 Advantages of alpha-lipoic acid and physical training combination in a Parkinson-like disease animal model by B.S.F. Mello; J.V. Santos; A.C.V. Gomes; R.C. Cordeiro; A.S. Monte; C.S. Custodio; B.M.M. Ribeiro; L.D. Belchior; D.S. Macedo (S232).
P.1.g.073 Modulation of 5-HT-Ach interactions in the hippocampus by newly synthesised peptidomimetics in an experimental model of aggression in rats by R. Klisurov; E. Encheva; L. Tancheva; L. Shikova; L. Alova; M. Kaneva; D. Tsekova (S232-S233).
P.1.g.074 Plasma concentrations of paroxetine among treatment responder inpatients at week one and before discharge by G. Eryilmaz; M.E. Ceylan; B. Onen Unsalver; I. Gogcegoz; S. Ozilhan; E. Saglam (S233-S234).
P.1.h.022 Role of monoaminergic receptors in the panic-like behaviour evoked in Swiss mice by confrontation with wild coral snakes by R.L. De Freitas; L.V. Rimi; A.F. Biagioni; W.A. Ubiali; N.C. Coimbra (S255-S256).
P.1.h.023 The role of fibroblast growth factor antisense in modulation of affective behaviour by E. Eren-Kocak; M. Yilmaz; K. Basar; Y. Ayhan; H. Ozdemir; Z.D. Sen (S256).
P.1.i.028 Emotion processing in eating disorders: an fMRI study by R.M. Molina-Ruiz; M. Marina Díaz-Marsá; T. Tomás García Saiz; E. Esther Via; H. Helena Trebbau; M. Mariano Rincón (S279-S280).
P.1.i.027 The influence of cross-sex hormone therapy on motor inhibition measured with the stop signal task and 7Tesla fMRI by M. Spies; G.S. Kranz; S. Ganger; R. Sladky; M. Küblböck; T. Vanicek; A. Hahn; C. Windischberger; S. Kasper; R. Lanzenberger (S279).
P.1.i.029 Working memory (WM) assessment in euthymic bipolar patients: a 3T functional magnetic resonance imaging (fMRI) study with N-back task by L. Cremaschi; M. Cristoffanini; B. Penzo; M.C. Palazzo; C. Dobrea; C. Cinnante; S. Avignone; B. Dell'Osso; F.M. Triulzi; A.C. Altamura (S280).
P.1.i.030 Default mode network functional connectivity in patients with temporal lobe epilepsy and comorbid depressive and anxiety symptoms by L. Shmeleva; A. Lebedev; A. Lebedeva (S281).
P.1.j.001 Cognitive function in recovered geriatric depressive patients by B. Kim; J. Chang; D. Lee; J. Park (S281-S282).
P.1.i.026 Cortical thickness differences in methamphetamine dependent individuals with and without a history of psychosis by A. Uhlmann; N. Koen; H. Sinclair; H. Temmingh; E. Meintjes; D.J. Stein (S278-S279).
P.1.i.025 Abnormal brain functioning during salience processing in patients with schizophrenic psychosis by A. Walter; R. Smieskova; A. Schmidt; A. Simon; T. Vogel; J.P. Roiser; A. Riecher-Rössler; S. Borgwardt (S277-S278).
P.1.i.021 Chronic cannabinoid treatment induces connectivity alterations in the juvenile rat brain evidenced by diffusion tensor imaging by M. Humbert-Claude; B. Larrat; M. Tanter; Z. Lenkei (S275-S276).
P.1.i.020 Grey matter volume abnormalities in adolescents at high risk for psychosis by G. Sugranyes; E. De la Serna; C. Espelt; A. Calvo; V. Sanchez-Gistau; O. Puig; S. Romero; M. Dolz; J. Castro-Fornieles; I. Baeza (S274-S275).
P.1.i.022 Effect of early stress on hippocampal gray matter is influenced by a functional polymorphism in EAAT2 in bipolar disorder by S. Poletti; D. Radaelli; C. Locatelli; C. Colombo; F. Benedetti (S276).
P.1.i.023 White matter abnormalities in children and adolescents with autism spectrum disorder and in their unaffected siblings: a diffusion tensor imaging study by M. Rosa; O. Puig; A. Calvo; N. Bargalló; R.M. Calvo (S276-S277).
P.1.i.024 Simultaneous PET-MR imaging of the effects of microdose challenges using [11C]AZ-10419369 in non-human primates by H.D. Hansen; J. Mandeville; L. Feng; C.Y. Sander; J.M. Hooker; C. Catana; B. Rosen; G.M. Knudsen (S277).
P.1.j.002 Memory impairment in old mice is differentially sensitive to different classes of antidepressants by Y. Li; C. Sanchez; M. Gulinello (S282).
P.1.j.003 Abnormal reward processing in the methylazoxymethanol (MAM) model of schizophrenia: neural and behavioural evidence by J. Francois; M. Conway; J. Huxter; J.P. Lowry; M. Tricklebank; G. Gilmour (S282-S283).
P.1.j.012 Cerebral regions associated with inhibition control on working memory in schizophrenia and their voxel-based morphometry by J.C. Yang; J.I. Park; Y.C. Chung; G.W. Kim (S288).
P.1.j.011 Synthesis and pharmacological evaluation of irreversible allosteric ligands for the M1 muscarinic acetylcholine receptor by B.J. Davie; C. Valant; B. Capuano; P.J. Scammells; A. Christopoulos (S287-S288).
P.1.j.013 Pharmacological characterisation and phase I evaluation in healthy volunteers of the nAChR agonist, AQW051 by C. Lopez Lopez; D. Johns; M. Weiss; D. Feuerbach (S288-S289).
P.1.j.014 Effects of chronic etanercept, a TNF-α inhibitor, on cognitive deficits in diabetic rats by S.S. Gocmez; T. Utkan; A. Karson; D. Bayramgurler (S289).
P.1.j.015 The neural basis of enhanced self-focus attention in patients with major depression by G. Wagner; C. Schachtzabel; U. Pietsch; G. Peikert; K.J. Bär (S290).
P.1.j.010 Neuropsychological impairment: the disturbed effect of self-processing in major depressive disorder by S. Liu; M. Yin; H. Zhu; J. Liu; H. Jia (S287).
P.1.j.009 Breaking evidence from a human object pattern separation test of disrupted hippocampal dentate gyrus activity in schizophrenics by K. Wesnes (S286).
P.1.j.005 Association between cognitive function, disability, productivity and quality of life among patients treated for depression by J.L. Kurlander; J.S. Samp; K.S. Akhras; P. Maruff; L.R. Kingery; B. Essoi; V. Walker (S284).
P.1.j.004 Cognitive functioning is associated with reduced motivation and mental fatigue in patients with coronary artery disease by J. Burkauskas; J. Brozaitiene; R. Bunevicius (S283).
P.1.j.006 Association between cognitive function and patient-reported depression severity among patients treated for depression by K.S. Akhras; J.C. Samp; J.L. Kurlander; V. Walker; L.R. Kingery; J. Jaeger; P. Maruff (S284-S285).
P.1.j.007 Impact of improved insight in schizophrenia: a double-blind lurasidone and quetiapine XR study by P. Harvey; C.O. Siu; J. Cucchiaro; A. Pikalov; A. Loebel (S285).
P.1.j.008 Computerised cognitive testing in the medical treatment of neurological and psychiatric disorders by K. Kurzbuch; W. Graf; B.S. Kasper; H. Stefan; E. Pauli (S285-S286).
P.1.i.019 Epistasis between catechol-O-methyltransferase and dopamine transporter genotypes on hippocampal volume in cannabis users and controls by A. Batalla; V. Lorenzetti; M. Yücel; C. Soriano-Mas; S. Bhattacharyya; R. Martín-Santos (S274).
P.1.i.018 Anterior cingulate cortex reactivity to emotion processing in premenstrual disphoric disorder by E. Comasco; A. Hahn; S. Ganger; M. Gingnell; E. Bannbers; L. Oreland; J. Wikström; R. Lanzenberger; I. Sundström-Poromaa (S273-S274).
P.1.h.032 Angiotensin (1–7) administration induces anxiolytic-like effects in elevated plus maze and decreased oxidative stress in the amygdala by A. Ciobica; W. Bild; M. Padurariu; V. Bild (S261).
P.1.h.031 The effects of intrathecal versus intraperitoneal vitamin C administration on pain models in mice by A. Luca; T. Alexa; A. Dondas; G.D. Andron; D. Negru; C.R. Bohotin (S260-S261).
P.1.i.001 Dopamine D2/3 receptor availability and human cognitive impulsivity: a high-resolution PET imaging study with [11C]raclopride by J.H. Kim; Y.D. Son; S.Y. Lee; Y.B. Kim; Z.H. Cho (S262).
P.1.i.002 Subgenual anterior cingulate cortical functional connectivity in treatment-resistant depression by C. Baeken; D. Marinazzo; G.R. Wu; P. Van Schuerbeek; J. De Mey; R. De Raedt (S262-S263).
P.1.i.003 PET brain imaging of neuropeptide Y2 receptors by D. Smith; M. Winterdahl; H. Audrain; A. Landau; P. Bonaventure; J. Shoblock; N. Carruthers; D. Swanson; D. Bender (S263-S264).
P.1.h.030 PWZ-029 alleviates MK-801-induced memory deficits in the rat: implications for the treatment of cognitive impairment in schizophrenia by S. Joksimovic; A.L. Obradovic; T. Timic; T. Radulovic; P. Biawat; J. Kovacevic; M. Milic; B. Batinic; J.M. Cook; M.M. Savic (S260).
P.1.h.029 MK-801-induced hyperlocomotion in rats is affected by modulation of α5-containing GABAA receptors by T. Timic; S. Joksimovic; A.L. Obradovic; M.M. Poe; P. Biawat; J. Ramerstorfer; B.L. Roth; W. Sieghart; J.M. Cook; M.M. Savic (S259-S260).
P.1.h.025 NMDA receptor antagonist 3-[(±)-2-carboxypiperazin-4-yl]propyl-1-phosphonic acid (CPP) impairs cognitive behavior in mice by D. Ciubotariu; A.S. Neculai-Valeanu; C.E. Lupusoru; L. Tartau (S257).
P.1.h.024 3,4-Methylenedioxyethylamphetamine (MDEA) provokes changes in the sequential structure of the agonistic behaviour of mice by A.T. Muela; M. Martm-López; M. Cavas; J.F. Navarro (S256-S257).
P.1.h.026 Effects of obestatin and its fragment (1–4) on algesthesia and behavioural activity in male wistar rats by E. Khirazova; M. Maslova; A. Guseva; A. Graf; A. Maklakova; N. Sokolova; A. Kamenskij; Z. Bespalova; D. Frid (S257-S258).
P.1.h.027 MBDB, a recreational drug similar to MDMA, alters sequential structure of agonistic behaviour in male mice by A.T. Muela; M. Martín-López; M. Cavas; J.F. Navarro (S258).
P.1.h.028 Selective antagonism at CRF1 receptor as a novel pharmacological treatment for binge-type eating disorders by M. Micioni Di Bonaventura; M. Ubaldi; K. Rice; M. Massi; R. Ciccocioppo; C. Cifani (S259).
P.1.i.004 Acute enhancement of serotonin neurotransmission with escitalopram on emotion processing: a randomized, crossover fMRI study by T. Outhred; P. Das; K.L. Felmingham; R.A. Bryant; P.J. Nathan; G.S. Malhi; A.H. Kemp (S264).
P.1.i.005 Acute neural effects of SSRIs versus NRIs on emotion processing: implications for differential treatment efficacy by T. Outhred; B.E. Hawkshead; T.D. Wager; P. Das; G.S. Malhi; A.H. Kemp (S264-S265).
P.1.i.014 Alterations of white matter microstructure in anorexia nervosa by E. Via; A. Zalesky; A. Fornito; I. García; L. Forcano; J. Pujol; F. Fernández-Aranda; J.M. Menchón; C. Soriano-Mas; N. Cardoner (S270-S271).
P.1.i.013 No effect of TPH1, MAO-A, 5-HT1A and 5-HT2A gene variants on 5-HT1A binding potential in healthy subjects measured with PET by P. Baldinger; M. Mitterhauser; M. Bilban; C. Kraus; J. Ungersboeck; M. Jeitler; W. Wadsak; D. Rujescu; S. Kasper; R. Lanzenberger (S270).
P.1.i.015 The effect of the brain-derived neurotrophic factor Val66Met polymorphism on human hippocampal volume – a meta-analysis by F. Harrisberger; R. Smieskova; A. Schmidt; A. Papassotiropoulos; S. Borgwardt (S271-S272).
P.1.i.016 Amphetamine pretreatment alters the response to a methylphenidate challenge: a pharmacological magnetic resonance imaging study by A. Schrantee; J.L. Tremoleda; M. Wylezinska-Arridge; W. Gsell; L. Reneman (S272).
P.1.i.017 Three week bright-light intervention has dose-related effects on threat-related corticolimbic reactivity and functional coupling by P.M. Fisher; M.K. Madsen; B. Mc Mahon; K.K. Holst; S.B. Andersen; H.R. Laursen; L.F. Hasholt; H.R. Siebner; G.M. Knudsen (S272-S273).
P.1.i.012 Habenular nuclei in different phases of major depressive disorder: a magnetic resonance imaging volumetric study by M. Carceller; M. Serra-Blasco; J. De Diego-Adeliño; Y. Vives-Gilabert; B. Gómez-Anson; D. Puigdemont; E. Álvarez; V. Pérez; M. Portella (S269-S270).
P.1.i.011 Prefrontal serotonin transporter binding is not associated with trait aggression and impulsivity in healthy subjects by S. Da Cunha-Bang; V. Frokjaer; B. McMahon; K. Holst; P. Jensen; G. Moos Knudsen (S268-S269).
P.1.i.007 The effect of bright light intervention on cerebral serotonin transporter binding by B. Mc Mahon; A.S. Andersen; L. Feng; M.K. Madsen; S. Lehel; M.M. Herth; P. Iversen; L. Hasholtd; G.M. Knudsen (S266).
P.1.i.006 Brain sonography as a novel method for detection of nuclei raphe lesion in suicidal patients and MDMA users by M. Budisic; D. Karlovic; D. Buljan; M. Strineka; V. Basic-Kes (S265-S266).
P.1.i.008 Bipolar disorder and magnetic resonance imaging by S.L. Romero Guillena; P. Aguilar Valseca; P. Vaquero Casado; E. Garcia Henche; B.O. Plasencia Garcia de Diego (S266-S267).
P.1.i.009 Default mode network alterations in refractory schizophrenia patients with auditory verbal hallucinations by A. Alonso-Solis; Y. Vives-Gilabert; E.M. Grasa; S. Durán-Sindreu; A. Keymer; A. Roldan; F. Nuñez-Marín; B. Gómez-Ansón; V. Perez; I. Corripio (S267-S268).
P.1.i.010 Transient and persistent brain abnormalities during mood episodes in schizoaffective disorder: a longitudinal fMRI study by M. Madre; J. Radua; E. Pomarol-Clotet; R. Salvador; P. McKenna; B. Amann (S268).